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I Introduction 
I.1 Atherosclerosis 
Atherosclerosis is the principal contributor to cardiovascular disease, which recently is the 
major cause of death and illness in developed countries (Libby 2002). Atherosclerosis is a 
process, which begins with the formation of so-called “fatty streaks” beneath the 
endothelium of the artery wall, followed by the development of atherosclerotic lesions, 
which are composed of layers of lipid-laden macrophages and smooth muscle cells (SMC). 
As the disease progresses, these lesions develop into more complex fibrous plaques 
(atheromas) (Ross 1993). Eventually, by unknown mechanisms, these plaques may become 
unstable leading to rupture and subsequent thrombus formation rather than luminal 
narrowing results in clinical events such as myocardial infarction and stroke (Fig. I.1) 
(Hansson 2005). 
Until the 1970s, atherosclerosis was linked with hypercholesterolemia without 
further knowledge of the mechanisms of plaque formation. Over the past decades, it has 
become evident that the retention of low-density-lipoproteins (LDL) and their oxidation 
(oxLDL) initiate an inflammatory response of the endothelium (Skalen et al. 2002; 
Leitinger 2003). After initiation of inflammation, endothelial cells (EC) and SMC as well 
as T lymphocytes and intimal macrophages secrete chemokines, which enhance the 
recruitment and transmigration of immune cells through the endothelium (Weber et al. 
2004). Thus, atherosclerotic plaques contain a large quantity of activated immune cells 
producing effector molecules like radicals, inflammatory cytokines and proteases that can 
destabilize the lesions and initiate thrombus formation (Jonasson et al. 1986; Stemme et al. 
1992; Hansson 2005). 
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Fig.I.1: Plaque rupture. Atherosclerotic lesions form beneath the endothelium of the innermost layer of the 
vessel wall, the intima. They consist of inflammatory and immune cells, connective-tissue elements, lipids, 
and debris. The center of an atheroma is composed of lipid droplets, immune and foam cells. Activated 
immune cells secrete proteases, coagulation factors and radicals, which lead to plaque rupture. The leaking 
thrombogenic material leads to blood clotting and occlusion of the artery (Hansson 2005) (image: 
http://www.nucleusinc.com). 
 
 
I.1.1 Therapeutic strategies 
Besides bypassing the diseased artery, a common treatment of advanced atherosclerosis is 
the enlargement of the vessel lumen by balloon angioplasty with subsequent insertion of a 
metal tube, the so-called stent, which helps keeping the vessel from collapsing. The vessel 
injury caused by angioplasty and the use of bare-metal-stents, however, bear a high risk of 
re-narrowing of the vessel due to inflammatory processes, also called restenosis/in-stent-
restenosis. The use of drug-releasing stents provided very promising results in preventing 
restenosis in randomized clinical trials, mostly performed with the antiproliferative agents 
sirolimus (Rapamycin) and paclitaxel (Muller et al. 2002). 
For high-risk patients, such as diabetics, different drug therapies are employed to 
reduce various risk factors. Statins (HMG-CoA reductase inhibitors) are used to lower the 
blood cholesterol level. The pain killer acetylsalicylic acid (Aspirin®), which also inhibits 
platelet aggregation, is applied in low doses to prevent thrombosis. Furthermore, two 
different drug types are implemented to reduce the heart rate and blood pressure. 
Angiotensin converting enzyme (ACE) inhibitors prevent the activation of the 
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vasoconstrictive peptide angiotensin II, and β-blockers inhibit the stimulating effects of the 
stress hormones adrenalin and noradrenalin by antagonizing their receptors. 
The establishment of aspirin, β-blockers, ACE-inhibitors, and lipid-lowering 
therapies have lowered the risk of future vascular events by about a quarter each in high-
risk patients (Yusuf 2002). However, random clinical trials and observative data are very 
contradictory. Though treatments after coronary events improved and reduced mortality by 
about 50% in western developed countries in the past 20 years, cardiovascular disease 
remains the single leading cause of death because of unsatisfactory preventive therapies 
and an unhealthy lifestyle of patients. Therefore, a great effort is made in order to find new 
therapeutic approaches, e.g. by targeting inflammatory mediators like cytokines or 
chemokines. 
 
I.2 Chemokines in atherosclerosis 
Chemokines are a superfamily of small (most being 8-10 kDa) chemotactic cytokines that 
function in leukocyte trafficking and activation (Reape and Groot 1999). Approximately 40 
different chemokines have been identified so far, which interact with about 17 different 
chemokine receptors expressed on different subsets of leukocytes. Chemokines can be 
classified according to the arrangement of the first two of four conserved cysteines at the 
N-terminus. The largest group is formed by the CC chemokines, where the cysteines are 
adjacent to each other, followed by CXC chemokines with the first cysteines separated by 
a single amino acid residue. Those chemokines are further classified according to the 
absence or presence of an N-terminal Glu-Leu-Arg sequence, the ELR motif. CXC 
chemokines containing the ELR motif, e.g. Growth related oncogene-α (Gro-α/CXCL1) 
and Interleukin-8 (IL-8/CXCL8) were found to be angiogenic factors in contrast to the 
ELR-lacking CXC chemokines like PF4, which mediates angiostasis (Maione et al. 1990; 
Strieter et al. 1995). 
Fractalkine is the only member of the CX3C group with a 3 amino acid spacing 
between the N-terminal cysteines, and there has been described a XC group, which 
consists of two chemokines, lymphotactin-α and -β, possessing only two of the four 
cysteines (Moser and Willimann 2004). Another family termed chemokine-like-function 
(CLF) cytokines has recently been proposed for small molecular mediators like defensins 
and macrophage migration inhibitory factor (MIF) that cannot be assigned to the known 
chemokine families but share structural and functional features and can signal through 
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chemokine receptors, e.g. CCR6 (Yang et al. 1999; Degryse and de Virgilio 2003). The 
chemokines involved in atherosclerosis are listed in Table I.1. 
 
 
Chemokine Target Receptor 
CC Chemokine   
I-309/CCL1  MM   CCR8 
MCP-1/CCL2  MM, TC, EC  CCR2 
MIP-1α/CCL3  MM, TC  CCR1/5 
MIP-1β/CCL4  MM, aTC, SMC  CCR5 
RANTES/CCL5  MM, aTC, DC   CCR1/3/5 
Eotaxin/CCL11  B, DC   CCR3 
MCP-4/CCL13  MM, aTC  CCR2/3 
TARC/CCL17  Th2, DC   CCR4 
PARC/CCL18  rTC  Unknown 
ELC/CCL19  aTC  CCR7 
MDC/CCL22  aTC   CCR7 
CXC Chemokine 
  
GRO/KC/CXCL1  MM, EC, SMC CXCR1/2 
IL-8/CXCL8  MM, EC, SMC  CXCR1/2 
Mig/CXCL9  aTC CXCR3 
IP10/CXCL10  aTC? CXCR3  
I-TAC/CXCL11  MM, aTC, SMC   CXCR3 
SDF-1α/CXCL12  TC, vascular 
progenitors  
CXCR4 
  TC, NK   
SR-PSOX/CXCL16    CXCR6  
CX3C Chemokine   
Fractalkine/CX3CL1  MM, aTC   CX3CR1 
CLF     
MIF  MM, TC  Unknown 
 
 
Tab. I.1: Chemokines in 
atherosclerosis. 
Cells affected by chemokines 
involved in atherosclerosis are 
monocytes/macrophages (MM), 
active or resident T cells or T cells 
in general (aTC, rTC and TC), 
smooth muscle cells (SMC), 
dendritic cells (DC), endothelial 
cells (EC), vascular progenitors 
and T helper cells (Th2) (adapted 
from Weber et al., 2004). 
 
Chemokines evoke cell responses by interacting with specific chemokine receptors, 
which are denominated according to their ligands (CXC, CC, XC, CX3C), plus R for 
receptor (Tab.I.1). These receptors are seven transmembrane-spanning receptors that signal 
through coupled heterotrimeric G proteins. Upon binding to their receptors chemokines 
induce a signal transduction cascade that leads to activation of protein kinases and an 
increase in intracellular Ca2+ (Horuk 2001). Eventually, cell activation leads to actin re-
arrangement, shape change and cell movement. 
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Chemokines trigger the atherogenic recruitment of mononuclear cells (Charo and 
Taubman 2004; Weber et al. 2004). In this regard, chemokines immobilized on the 
endothelial surface rather than their soluble counterparts activate integrins such as the β2 
integrin lymphocyte function-associated antigen-1 (LFA-1) and very late antigen-4 (VLA-
4), which mediate the arrest of rolling leukocytes on the arterial wall and their 
transmigration into the tissue to the site of inflammation (Fig.I.2) (Weber et al. 1999; Ley 
2003; Laudanna and Alon 2006). In the context of atherosclerosis, this has been best 
established for the platelet-derived CC chemokine Regulated upon Activation, Normal T 
cell Expressed and Secreted (RANTES/CCL5), and for the CXC chemokines and CXCR2 
ligands Gro-α and IL-8 (Charo and Taubman 2004). 
 
Inactive
integrins
Chemokines
2. Rolling
leukocyte
Endothelium
1. Tethering
3. Firm arrestActive
integrins
4. Transmigration
Blood flow
Tissue
Integrin ligands
 
Fig.I.2: Leukocyte extravasation from the blood flow into inflamed tissue. A multistep cascade leads to 
the activation of integrins and their ligands by chemokines. The steps involved in this process are tethering, 
rolling, integrin activation, firm adhesion and transmigration across the endothelial layer modified from 
Sackstein (2005). 
 
I.2.1 The chemokine RANTES in atherosclerosis 
In the 1980’s, RANTES has been identified as a CC-class chemokine expressed by T 
lymphocytes, which recruits T cells, eosinophils and macrophages to sites of inflammation 
(Schall et al. 1988; Schall et al. 1990). Further studies demonstrated an upregulation of 
RANTES in activated vascular SMC (VSMC) as well as its expression in several cell types 
involved in accelerated atherosclerosis and in neointimal lesions after vascular injury 
(Pattison et al. 1996; Jordan et al. 1997; von Hundelshausen et al. 2001). Here, it became 
evident that one of the major effectors of atherogenesis is the platelet-derived RANTES, 
which is deposited on the inflamed endothelium where it may trigger subsequent monocyte 
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arrest. 
The known RANTES receptors are CCR1, CCR3 and CCR5. CCR1 and CCR3 are 
involved in RANTES-triggered eosinophil activation, though CCR3 seems to play a minor 
role in RANTES actions (Elsner et al. 1997). The effects of RANTES on leukocyte arrest 
and transmigration are mediated by specialized roles of CCR1 and CCR5, respectively 
(Weber et al. 2001), and a mouse model of atherosclerosis recently revealed that CCR5 but 
not CCR1 is the crucial receptor promoting atherogenesis (Braunersreuther et al. 2007), 
identifying CCR5 as a promising therapeutic target. Blocking the receptor with an 
antagonist called Met-RANTES (recombinant RANTES which retains its N-terminal 
methionine) significantly reduced injury-induced neointima hyperplasia and 
atherosclerosis progression in hypercholesterolemic mice (Veillard et al. 2004). Another 
therapeutic approach could be made by interfering directly with the chemokine production. 
 
RANTES expression 
Through the identification of a large number of consensus elements for T cell specific and 
ubiquitous DNA binding proteins in the RANTES promoter (Nelson et al. 1993) (Fig. I.3), 
some of the mechanisms regulating the expression of RANTES have been determined. For 
instance, promoter studies revealed the constitutive and interferon (IFN)-γ- or tumor 
necrosis factor (TNF)-α-inducible transcription factors IFN-regulatory factor 1 (IRF-1) and 
nuclear factor-κB  (NF-κB or p50/p65), which synergistically activated the RANTES 
promoter (Genin et al. 2000; Lee et al. 2000). In monocytes and the monocytic cell line 
MonoMac6, a lipopolysaccharide (LPS)-inducible promoter module for cAMP response 
element binding protein/activator protein-1 (CREB/AP-1) has been identified (Boehlk et 
al. 2000). Additionally, RANTES expression in monocytes has been shown to be mediated 
by the constitutive binding of both CCAAT enhancer binding proteins (C/EPBs) (positions 
-125/-99) and Sp1 at position -73 and the binding of NF-κB following LPS stimulation 
(position -34) (Fessele et al. 2001). Another study using airway SMC revealed that AP-1 
and nucleofactor of activated T cells (NF-AT) lead to TNF-α-induced promoter activation, 
whereas here NF-κB binding was not necessary (Ammit et al. 2002). Apart from IRF-1, 
NF-κB, AP-1 and other transcription factors, DNAse I footprinting also showed that the 
RANTES promoter contains possible binding sites for the Y-box binding 
protein-1 (YB-1) at positions -209 and -187  implying a regulatory role for YB-1 in 
RANTES expression (Nelson et al. 1993). 
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CREB/AP-1 FLAT IRF-1/ETS C/EBP Sp1/NFκB
YB-1 ?
G                 C             D                E             A/B
 
Fig. I.3: RANTES promoter modules. The RANTES promoter features 5 different regulation modules (A-
G) for several transcription factors. Additionally, the promoter contains a possible binding region for YB-1 at 
position -187 to -209; FLAT = RANTES C site binding factor of late-activated T cells; Adapted from Fessele 
et al., 2002. 
 
 
Transcription factor YB-1 
The cold shock protein YB-1, also termed p50 and DNA binding protein B (dbpB), 
belongs to the evolutionary ancient and highly conserved group of 
Y-box binding proteins, which control the expression of a large number of gene products. 
In the cytoplasm it is cleaved by the 20s Proteasome and translocates to the nucleus 
(Sorokin et al. 2005), where it preferentially binds to a DNA sequence containing the so-
called Y-box or inverted CCAAT-box (CTGATTGGC/TC/TAA) (Ting et al. 1994). This 
sequence is present in a variety of eukaryotic genes, such as those coding for the major 
histocompatibility complex (MHC) class II genes. By binding to this regulatory sequence, 
YB-1 can act either as a trans-repressor or -activator, and the inhibition or activation of a 
gene can be cell type-specific as shown for the matrix metalloprotease (MMP)-2 gene 
(Mertens et al. 1997). YB-1 not only controls gene expression on the DNA transcription 
level, but also on the translational level by splicing RNA precursors e.g. by interacting 
with the splicing factor SRp30c or binding to close proximity of the 5’ cap-structure of the 
mRNA, thereby silencing and stabilizing the mRNA (Raffetseder et al. 2003; Evdokimova 
et al. 2006). Furthermore, YB-1 functions are likely beyond the regulation of gene 
expression, as it has been shown to relocate to the nucleus and bind to DNA repair proteins 
(Gaudreault et al. 2004). 
 
An increased expression of YB-1 in certain inflammatory diseases has been 
described, e.g. by activated eosinophils in allergic asthma (Capowski et al. 2001), where 
YB-1 prolonged their survival and thus exacerbated disease, or by mesangial cells in 
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mesangioproliferative disease (van Roeyen et al. 2005). YB-1 might also play a role in 
atherogenesis, because the proximal promoter region of the RANTES gene displays two 
possible binding sites for YB-1, thus suggesting a regulatory role for YB-1 in the 
expression of the atherosclerosis-promoting chemokine RANTES. 
 
I.2.2 The chemokine-like function chemokine Macrophage 
Migration Inhibitory Factor (MIF) 
40 years ago,  the cytokine MIF was first identified in context with delayed-type 
hypersensitivity as a T cell-derived inhibitor of random macrophage migration (Bloom and 
Bennett 1966; David 1966). It was later found to be also produced by other cells such as 
macrophages and monocytes and pituitary cells, where it is released in a “hormone-like” 
fashion (Bernhagen et al. 1993; Calandra et al. 1994). Nowadays, MIF is known to be an 
important mediator of host immune response promoting innate immunity by Toll-like 
receptor 4 upregulation and antagonizing the anti-inflammatory actions of glucocorticoids 
(Calandra and Bucala 1995; Roger et al. 2001). Moreover, in contradiction to its name, 
MIF recruits leukocytes to sites of inflammation in a chemokine-like manner as e.g. 
observed in a rat model of immunologically induced glomerulonephritis (Lan et al. 1997). 
Since the 1990’s several immune-mediated diseases have been associated with MIF such 
as rheumatoid arthritis (RA) (Leech et al. 1999) and systemic lupus erythematosus (Hoi et 
al. 2006). An association of a MIF promoter CATT tetranucleotide polymorphism with the 
severity of these diseases has been documented (Baugh et al. 2002; Sanchez et al. 2006).  
 
MIF and atherosclerosis 
MIF’s role in atherosclerosis progression has been established more recently. Schober et 
al. observed a significant reduction of macrophages and macrophage-derived foam cells in 
wire injury-induced neointimal lesions of hyperlipidemic mice after treatment with a MIF-
blocking monoclonal antibody (mAb). Conversely, the content of SMC and collagen type I 
was increased indicating a more stable plaque phenotype. As an underlying mechanism, 
the authors found that incubation of aortic EC with recombinant MIF for 2 h can trigger 
monocyte arrest under flow conditions, while endothelial MIF mediates arrest after 
exposure to oxidized low-density-lipoprotein (oxLDL) (Schober et al. 2004). Accordingly, 
the retardation of diet-induced atherogenesis in LDL-receptor (LDLR)-/- mice by genetic 
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deletion of MIF was manifest by a decrease in intimal thickening, lipid deposition and 
protease expression (Pan et al. 2004). In a mouse model of spontaneous atherosclerosis, 
blockade of MIF also led to the reduction of macrophages in the aortic wall as well as to 
the inhibiton of several inflammatory mediators as ICAM-1, MMP-2 and TNF (Burger-
Kentischer et al. 2006).  These findings support a model, according to which MIF may 
directly affect endothelial-monocyte adhesion by a mode of action resembling that of 
immobilized chemokines in atherogenesis. 
 
MIF structure and functional features 
Human MIF consists of 115 amino acids (aa), has a molecular weight of 12.34 kDa and 
shows a 90% homology to murine MIF. The X-ray crystal structure revealed a MIF trimer 
of identical subunits (Sun et al. 1996), which form a circular protein with an interior 
hydrophobic solvent accessible channel with unknown function. Each monomer contains 
two antiparallel α-helices that pack against a four-stranded β-sheet (Fig. I.4, A). Reports 
about the oligomerization state of MIF have been contradictory and have varied with the 
techniques applied, and a study using gel filtration and cross-linking experiments proved 
that MIF forms monomers, dimers, and trimers in physiological solution, whereas the 
trimer is only a minor species (Mischke et al. 1998). 
 Apart from its unique structure that is not in line with neither structural group of 
chemokines, the MIF monomer bears a striking resemblance to the IL-8 dimer (Fig. I.3). 
Also, MIF displays a pseudo-ELR motif formed by an arginine (R11) and the aspartic acid 
residue at position 44 (D44) (Fig. I.4). 
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Fig. I.4: Architectural homology of the MIF monomer and IL-8 dimer. (A) MIF monomer with 
highlighted pseudo-ELR motif (red circle); (B) IL-8 dimer with side chains of one of the two ELR motifs 
(red circle). 
 
Besides its similarity to IL-8, structural homologies of the MIF monomer and trimer 
with microbial enzymes have been disclosed (Chook et al. 1994; Subramanya et al. 1996), 
and in compliance with that, three enzymatic activities have been reported for MIF.  First, 
a glutathione S-transferase activity and a tautomerase activity have been documented 
(Blocki et al. 1993; Rosengren et al. 1996), and it has been shown that MIF exhibits a thiol 
protein oxidoreductase activity and that this activity is dependent on the presence of the 
catalytic center that is formed by cysteine residues 57 and 60, the so-called CALC motif 
(Cys-Ala-Leu-Cys) (Kleemann et al. 1998). Mutation of the CALC motif did not only lead 
to the loss of the oxidoreductase activity, but also to the immunogenic function of MIF, 
whereas the inhibition of MIF’s tautomerase activity by deleting or substituting the N-
terminal proline did not interfere with its immunogenic function (Bendrat et al. 1997; 
Kleemann et al. 2000). 
 
MIF interaction partners 
MIF uptake into various immune and non-immune cell types by non-receptor mediated 
endocytosis and the identification of three intracellular proteins that directly interact with 
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MIF, supported the view that MIF fulfills intracellular functions: 
 
1. The first intracellular MIF-binding protein, identified by yeast-two-hybrid 
screening, was the c-Jun activation domain binding protein-1 (Jab1), which is a component 
of the COP9 signalosome (Kleemann et al. 2000). By binding to Jab1, MIF prevents the 
activation of AP-1 regulated gene transcription and the degradation of the cell cycle 
inhibitor p27Kip1. Thus, MIF blocks Jab1-mediated rescue from growth arrest (Fig.I.4). The 
authors suggested that MIF’s counter-regulatory actions to glucocorticoids were mediated 
by blocking Jab1-binding to steroid hormone receptors. For the androgen receptor this 
theory was disproved; MIF did not modulate Jab1-mediated co-activation of the androgen 
receptor (Berndt et al. 2007). 
Conversely, Jab1 is also associated with p53 degradation (Oh et al. 2006), and MIF 
has been shown to inhibit p53-mediated apoptosis and cell growth, thus linking 
inflammation and tumorigenesis (Hudson et al. 1999; Fingerle-Rowson et al. 2003). MIF-
mediated apoptosis inhibition was associated with a reduced p53 level in the cell and 
dependent on cyclooxygenase 2 (Cox-2) (Mitchell et al. 2002) (Fig.I.4). These data point 
towards a possible cooperation between MIF and Jab1 in p53 degradation by inducing  
AP-1-mediated Cox-2 expression. 
 
2. Jung et al. (2001) discovered that the thiol-specific antioxidant protein PAG binds 
to MIF under reducing conditions and that PAG dose-dependently inhibits MIF D-
dopachrome tautomerase activity. Likewise, MIF inhibits the antioxidant activity of PAG. 
 
3. As revealed by yeast-two-hybrid screening, BNIPL (Bcl-2/adenovirus E1B 19 kDa 
interacting protein 2-like), an apoptosis-associated protein interacts with MIF (Shen et al. 
2003). The authors suggest that BNIPL may be involved in regulation of MIF-mediated 
cell proliferation. 
 
4. The only known cell surface receptor for MIF is CD74, the invariant chain of major 
histocompatibility complex (MHC) II that is expressed in small quantities in a large 
number of cells (Leng et al. 2003). CD74 can mediate sustained activation of extracellular-
regulated and mitogen-activated protein kinases (ERK-MAPK) and has been proposed to 
associate into a signaling complex with MIF, CD44 and Src-family tyrosine kinases (Shi et 
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al. 2006) (Fig.I.4). It has recently been demonstrated that protein kinase PI3K/Akt-
mediated apoptosis was dependent on MIF-CD74-Src signaling triggered by exogenous 
MIF or endogenous MIF secretion, which was attenuated by Jab1 (Lue et al. 2007). 
Furthermore MIF’s ability to inhibit p53-dependent apoptosis was dependent on CD74 and 
CD44 (Shi et al. 2006). Whether CD74 mediates MIF internalization and/or interaction 
with Jab1 still remains to be elucidated. 
 
As not all cells targeted by MIF, i.e. neutrophils or fibroblasts express surface CD74, 
it seems likely that another receptor confers MIF’s pro-inflammatory functions. Because 
the existing data on MIF’s molecular mechanism do not explain how MIF exhibits its 
chemokine-like functions, and taking into account that the MIF monomer resembles the 
IL-8 dimer, it stands to reason that one or more chemokine receptors may be involved in 
MIF action (Fig.I.5). 
 
Src-kinase
CD44
JAB-1
PI3K/Akt
endo-
cytosis CD74
MAPK/ERK p53
MIF
intracellular
extracellular
p27Kip1
growth arrest
AP-1
gene expression
e.g.
JAB-1
COX-2Cyclin-D
Gαi
GPCR 
?
apoptosis
inhibition
apoptosis
inhibition
 
Fig.I.5: MIF’s mechanism of action. MIF (blue trimer) is internalized and interacts with Jab1, thereby 
stabilizing p27kip1 and inhibiting AP-1-induced gene expression. MIF also binds to CD74, leading to a 
sustained activation of MAPK/ERKs through CD44 and Src-kinases, which promote gene expression. MIF-
mediated apoptosis inhibition through PI3K/Akt depends on CD74 as well as apoptosis inhibition by p53 
degradation. It remains to be elucidated, if Jab1 is involved in MIF-mediated p53 degradation. MIF may 
activate cells in chemokine-characteristic way through binding to a GPCR (modified from Morand et al., 
2006) 
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I.3 Aim of this study 
This work was aimed at clarifying molecular mechanisms of two different mediators 
involved in atherogenesis. To get a better understanding of how chemokines and CLF 
chemokines trigger atherosclerosis and how their exacerbating effects on the disease may 
be diminished, two different approaches were pursued: 
For one, the aim was to gain further insights in the expression regulation of a 
prominent chemokine, i. e. the CC chemokine RANTES. As the RANTES gene features 
two possible binding sites for the transcription factor YB-1 in the proximal RANTES 
promoter region, it was investigated if YB-1 regulates RANTES expression in vascular 
SMC and macrophages. Furthermore, the inflammatory effects of YB-1-regulated 
RANTES were analyzed in terms of leukocyte recruitment in vitro and neointima 
formation in a mouse model of restenosis. 
The second approach intended to clarify the down-stream effects of a newly 
discovered CLF chemokine, i.e. the mediator protein MIF. In order to obtain a detailed 
overview of MIF’s chemokine-like functions, it was tested whether MIF is able to provoke 
cell responses typical for a certain subclass of chemokines, the arrest chemokines, such as 
leukocyte arrest, integrin activation and calcium mobilization. Furthermore, it was tested if 
these chemokine properties are conferred by a chemokine receptor, and if MIF/GPCR 
interactions were required for inflammatory cell recruitment in atherogenesis. 
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Table II: Flow chart. Brief summary of the questions addressed in this study and performed experiments. 
Identification of a protein
involved in RANTES regulation
Identification of a MIF receptor
and novel chemokine functions
Does YB-1 regulate RANTES 
expression in SMC and 
macrophages?
DNA binding studies, 
promoter reporter studies with SMC 
and a macrophage cell line,
real time-PCR, ELISA
Does YB-1-regulated RANTES 
mediated monocyte recruitment?
parallel plate flow chamber adhesion
assays
Is YB-1 involved in atherosclerosis
progression?
mouse model of restenosis with
lentiviral knock-down of YB-1,
evaluation of plaque area and 
macrophage content, 
RANTES expression in plaque area
Does MIF trigger leukocyte arrest
through GPCRs and CD74?
parallel plate flow chamber adhesion
assays with blocking antibodies, 
real time-PCR, ELISA
Does MIF directly provoke rapid 
cell responses in a 
chemokine-like fashion?
integrin activation assay, 
calcium mobilization
Does MIF bind to a GPCR and 
is there an interaction of GPCRs
and  CD74?
FACS assay with fluorescein-MIF,
coimmunoprecipitations
What impact does a MIF/GPCR
interaction have on inflammatory
cell recruitment and 
atherosclerosis?
ex vivo and in vivo perfusion of 
murine carotid arteries, 
peritonitis model,
plaque regression experiments
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II Material and Methods 
Protocols were adapted from standard protocols (Sambrook and Russell, 2001) if not stated 
otherwise. All solutions were prepared with double distillated water (Heraeus Destamat, 
Heraeus, Germany) or Millipore water (Milli-Q Plus ultrapure purification, Millipore, 
MA). Reagents were from Fluka (Buchs, Switzerland), Sigma (Deisenhofen, Germany), or 
Roth (Karlsruhe, Germany) if not stated otherwise. All animal studies were approved by 
local authorities and complied with German animal protection law. 
 
II.1 General equipment 
autoclave Systec 2540EL (Systec, Wettenberg, Germany) 
balance Analytical Plus, (Ohaus, Pine Brook, NJ, USA) 
centrifuges Eppendorf 5417C (Eppendorf, Hamburg, Germany), Heraeus 
Labofuge 400 and Heraeus Multifuge 3 S-R (Heraeus, Osterode, 
electroporators Gene-pulser II (Bio-Rad, Hercules, CA, USA), Nucleofector 
device (Amaxa, Cologne, Germany) 
flow cytometers FACSCalibur, FACSAria (BD Biosciences, San Jose, CA, USA) 
fluorescence plate reader SpectraFluor Plus (Tecan, Crailsheim, Germany) 
gel electrophoresis Mini-sub cell GT (Bio-Rad, Hercules, CA, USA) 
laminar flow hood Herasafe (Heraeus, Osterode, Germany) 
microscopes Olympus IX71 and BX51 (Olympus Optical, 
Hamburg,Germany), Leica DMLB (Leica, Wetzlar, Germany) 
PCR thermocyclers MyCycler (Bio-Rad, Hercules, CA), DNA Engine Opticon (MJ 
Research, Hercules, CA, USA) 
pH-meter InoLab level 1 (WTW, Weilheim, Germany) 
spectrophotometer GeneQuant (Amersham Biosciences, Uppsala, Sweden) 
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II.2 General solutions 
HH-buffer Hank’s buffered salt solution (HBSS), 0.5% (w/v) BSA, 10 mM 
HEPES, pH 7.4 
MOPS-buffer  1% (w/v) human serum albumin, 145 mM NaCl, 4.7 mM KCl, 2mM 
CaCl2, 1.2 mM MgSO4, 5 mM glucose, 2 mM sodium pyruvate, 2 
mM MOPS, and 1.2 mM NaH2PO4, pH 7.5 
PBS  37 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4, pH 
7.4 (PAA laboratories, Linz, Austria) 
TBS 137 mM NaCl, 2.7 mM KCl, 25 mM Tris-HCl, pH 7.4 
 
II.3 Mice 
MIF-deficient mice (Mif-/-) were crossbred with low-density lipoprotein receptor (LDLR)-
deficient mice (Ldlr-/-; Charles River Laboratories, Belgium) to establish Mif+/-/Ldlr-/- mice 
(all C57BL/6). Mif+/-Ldlr-/- animals of the F9 generation were used to generate Mif-/-/Ldlr-/- 
mice and Ldlr-/- littermates. Transgenic mice were fertile and showed no phenotypical 
abnormalities. 
Wild-type C57BL/6, Apolipoprotein E deficient (Apoe-/-) and Apoe-/-/Ccr5-/- mice 
were obtained from the local animal breeding facility (University Hospital, Aachen), and 
Cxcr2-/- mice on a BALB/c background and wild-type BALB/c mice were from the 
Jackson Laboratory (Bar Harbour, ME, USA). All studies with mice were approved by 
local authorities and complied with German animal protection law. 
 
II.4 Chemokines, antagonists, and recombinant proteins 
Biologically active recombinant human MIF, and labeled MIF with biotin or fluorescein, 
was from the Departmend of Biochemistry, University Hospital (UK) Aachen, Germany. 
Recombinant YB-1 was prepared from a pRSET vector (Invitrogen, Karlsruhe, Germany) 
containing an insert encoding for a hexahistidine T7 epitope-YB-1 fusion protein as 
described (Mertens et al. 1998). 
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The following chemokines were purchased from Peprotech (Rocky Hill, NJ, USA): 
IL-8 interleukin 8/CXCL8 
Gro-α growth related oncogene-α/CXCL1 
NAP-2 neutrophil activating peptide 2/CXCL7 
RANTES regulated upon activation normal T cell expressed and secreted/CCL5 
IP-10 IFN-inducible protein 10/CXCL10 
SDF-1α stromal cell-derived factor 1α/ CXCL12 
IFN-γ interferon-γ 
TNF-α tumor necrosis factor-α 
 
 
Recombinant human VCAM-1.Fc chimera was purchased from R&D Systems 
(Minneapolis, MN, USA). The small-molecule CXCR4 antagonist AMD3465 was 
provided by Anormed Inc. (Vancouver, Canada, USA) and the RANTES receptor 
antagonist Met-RANTES was kindly provided by Amanda Proudfoot (Serono International 
S.A., Geneva, Switzerland). Pertussis toxin (PTX) was obtained form Merck (Darmstadt, 
Germany). 
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II.5 Antibodies 
 
II.5.1 Primary Antibodies 
RII115 mouse-αhuman CXCR2 monoclonal antibody (mAb) (kind gift of A. 
Ludwig and E. Brandt, Department of Immunology and Cell Biology, 
Forschungszentrum Borstel) 
327C mouse-αhuman mAb, which binds to an activation epitope corresponding 
to the extended high affinity conformation of αLβ2 (Shamri et al. 2005) 
(provided by D. Staunton, Department of Biomedical Engineering, Genome 
and Biomedical Sciences Facility, University of California at Davis) 
Ka565 
rabbit-αhuman MIF pAb (Department of Biochemistry, University Hospital 
Aachen (UK Aachen, Germany) 
α-SMA mouse-αhuman α-actin mAb (clone 1A4, Dako, Glostrup, Denmark) 
Mac2 rat-αmouse mAb (clone M3/38, Cedarlane Laboratories, Ontario, Canada) 
αRANTES goat-αhuman mAb (clone C19, Santa-Cruz Biotechnology, CA, USA) 
αYB-1  pAb raised against an oligopeptide within the N-terminal domain of YB-1 
(P.R. Mertens, UK Aachen) 
MOMA-2 rat-αmouse mAb, macrophage marker (clone MCA519, AbD Serotec, 
Düsseldorf, Germany) 
CD3 mouse-αhuman mAb, T-cell marker (clone PC3/188A, Santa-Cruz 
Biotechnology) 
 
 
II.5.2 Directly conjugated antibodies 
CXCR2-FITC mouse-αhuman mAb, FITC-conjugated (clone 6C6, BD 
Pharmingen, Heidelberg, Germany) 
CD115-PE   rat-αmouse mAb, PE conjugated, monocyte marker (clone AFS98, 
eBiosciences, San Diego, CA, USA) 
Gr-1-perCP rat-αmouse mAb, perCP-conjugated, mature granulocyte marker 
(clone RB6-8C5, BD Pharmingen)  
F4/80-Biot rat-αmouse mAb, biotinylated, mature macrophage marker (clone 
A3-1, Serotec) 
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II.5.3 Blocking antibodies 
NIHIIID9  mouse-αmouse MIF mAb raised against purified recombinant mouse 
MIF (Lan et al. 1997) 
αGro-α mouse-αhuman mAb, clone 20326 (R & D Systems, Minneapolis, MN, 
USA) 
αKC rat-αmouse mAb, clone 124014 (R&D Systems) 
αIL-8 mouse-αhuman mAb, clone 6217 (R & D Systems) 
αSDF-1α mouse-αhuman/mouse mAb, clone 79014 (R & D Systems) 
αCXCR1 mouse-αhuman mAb, clone 42705 (R & D Systems) 
αCXCR2 mouse-αhuman mAb, clone 48311 (R & D Systems) 
αCXCR4 mouse-αhuman mAb, clone 44708 (R & D Systems)  
αCD74 mouse-αhuman (clone M-B741, BD Pharmingen) 
TS1/18  mouse-anti human mAb, specific for the β2 subunit of human αLβ2, 
purified from hybridoma cell supernatants by protein G chromatography 
(performed by Line Fraemohs, UK Aachen) 
HP2/1  mouse-αhuman mAb, specific for the α4 subunit of human VLA-4 
(Immunotech, Marseille, France) 
 
II.5.4 Isotype controls 
mouse IgG1/IgG2b/IgG2a (all from R & D Systems)   
rat IgG1/ IgG2b/ IgG2a (all from Serotec) 
rabbit IgG  Department of Biochemistry, UK Aachen 
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II.5.5 Secondary antibodies 
goat-αmouse-IgG  fluorescein isothiocyannate (FITC)-conjugated (Sigma) 
donkey-αmouse-IgG FITC-conjugated (Santa-Cruz Biotechnology) 
goat-αrabbit-IgG FITC-conjugated (Santa-Cruz Biotechnology) 
donkey-αrat-IgG FITC-conjugated (Santa-Cruz Biotechnology) 
donkey-αgoat-IgG cyanine 3 (Cy3)-conjugated (Santa-Cruz Biotechnology) 
donkey-αmouse-IgG Cy3-conjugated (Santa-Cruz Biotechnology) 
goat-αmouse-IgG horseradish peroxidase (HRP)-conjugated (Serotec) 
 
II.6 Mammalian cell culture 
Cell culture with mammalian cells was performed under sterile conditions in a laminar 
flowhood. Cells were maintained in a CO2-incubator at 37°C and a humidified 5% CO2 
atmosphere. Cells were cultured in growth medium supplemented with 10-20% (v/v) fetal 
calf serum (FCS), 4 mM L-glutamine and 50 µg/ml gentamicin or penicillin (100 
U/mL)/streptomycin (100 µg/mL) (PAA,  Pasching, Austria) to avoid contamination with 
bacteria. Cells used in this study and their optimal growth media are listed in (Tab.II.1). 
FCS was incubated at 56°C for 30 min to inactivate the complement system and stored at -
20°C until use. All media and solutions used for cell culture were from Gibco if not stated 
otherwise and purchased sterile or sterilized through a 0.2 µm filter. All cell lines were 
regularly tested to be mycoplasma free by the VenorGeM Mycoplasma detection kit™ 
(Minerva Biolabs, Berlin, Germany). 
 
II.6.1 Culturing of adherent cell monolayers 
Adherent cell lines were grown until confluence and then passaged by trypsinization. The 
monolayer was first washed with phosphate buffered saline (PBS) and then incubated 1-2 
min with 0.25% (v/v) trypsin/0.04% EDTA at 37°C. After detachment of the monolayer, 
trypsin was inactivated by the addition of medium containing FCS. For subculturing, cells 
were harvested by centrifugation (5 min, 200 g, at room temperature (RT)) and then split 
with a subculturing ratio between 1:3 and 1:10. 
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II.6.2 Culturing of cells in suspension 
Cells growing in suspension were cultured at a density of 105 - 106 cells/ml. Cells were 
harvested by centrifugation (5 min/200 g/RT). 
 
 
II.6.3 Freezing and thawing of mammalian cells 
Freeze stocks of cell lines were stored in 1.8 ml cryovials in liquid nitrogen. Cells were 
first harvested and then resuspended at a concentration of 106 – 107 cells/ml in ice-cold 
complete medium containing 10% (v/v) dimethylsulfoxide (DMSO). The cryovials were 
placed overnight (o.n.) at -80°C in a cryocontainer to assure slow cooling and then 
transferred to liquid nitrogen for long-term storage. For thawing of cells, cryovials were 
rapidly thawed in a 37°C water bath. Cells were slowly added to 4 mL warm growth 
medium, centrifuged and resuspended in growth medium. 
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Tab.II.1: List of the primary cells and cell lines used in this study 
Primary cells Origin/Phenotype Source Medium 
HAoEC human aortic PromoCell Endothelia Growth   
  endothelial cells (Heidelberg, Germany) Medium MV (PromoCell) 
HVSMC human vascular  smooth  provided by R. Blindt,  Smooth Muscle Cell Growth 
  muscle cells (SMC) Med. Clinic I, UK Aachen Medium 2 (PromoCell) 
  from Arteria mammaria      
rSMC SMCs from media and from Alma Zernecke,  isolated and cultured as  
  neointima of Sprague- Institute for Molecular described (Zeiffer et al.  
  Dawley rats Cardiovascular Research 2004) 
    (IMCAR), UK Aachen  
HCASMC human coronary artery   PromoCell Smooth Muscle Cell Growth 
  SMCs    Medium 2 (PromoCell) 
T cell blasts from  peripheral blood    RPMI 1640 + 10% FCS,  
  mononuclear cells (PBMCs)   2 mM glutamine, 5 µg/mL  
  healthy donors   PHA, 100 U/mL IL-2 
neutrophils from  PBMCs of    
  healthy donors  not cultured 
        
monocytes from  PBMCs of    
  healthy donors  not cultured 
        
Cell lines Origin/Phenotype Source Medium 
MonoMac6 human acute monocytic  from Ziegler-Heitbrock, RPMI 1640 + 10% FCS,  
  leukemia University fo Leicester,  1x MEM non-essential  
    UK amino acids, 9 µg/ml 
     insulin, 1 mM oxalacetate  
      and 1 mM pyruvate 
CHO/ ICAM-1 chinese hamster ovary  Revotar (Henningsdorf, DMEM/F12-GlutaMax +  
 cells expressing inter- Germany) 10% FCS, 800µg/mL 
  cellular adhesion  G418 
  molecule-1 (ICAM-1)     
SVEC Simian virus transduced  ATCC (Manassas, USA) DMEM + 10% FCS 
  mouse endothelial cells     
Jurkat human T cell leukemia ATCC  RPMI 1649 + 10% FCS 
  cells     
L1.2  murine pre-B lymphoma from Dr. M. Locati , RPMI 1640 + 10% FCS,  
    University of Milano,  1 mM pyruvate, 50 µM β- 
     Italy -mercaptoethanol, 10 mM HEPES 
HEK-293 human embyonic kidney ATCC DMEM/F12-GlutaMax + 10% FCS 
RAW264.7 murine macrophages ATCC DMEM + 10% FCS 
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II.6.4 Isolation of PBMC 
PBMC were isolated from venous blood of healthy donors by Ficoll-hypague density 
gradient centrifugation. After dextran sedimentation, the plasma supernatant was carefully 
overlayed on Biocoll separating solution, density 1.077 g/ml (Biochrom, Berlin, Germany) 
and centrifuged (20 min/450 g/RT/without brake). The PBMC interface layer was 
harvested, diluted in PBS and centrifuged (5 min/400 g/RT). The mononuclear cells were 
washed twice with PBS, and the viability was determined by trypan blue exclusion. 
 
II.6.5 Isolation of T cells 
Total T cells from PBMC (0) were isolated by use of the CD3 Dynabeads™ (Miltenyi 
Biotec, Bergisch Gladbach, Germany) according to the manual. Subsequently the T cells 
were cultured in RPMI 1640 medium containing 10% FCS. In order to stimulate 
proliferation of the T cells, the medium was supplemented with 100 U/mL IL-2 and 
5µg/mL phytohemagglutinin (PHA), which initiates mitosis. After 3-4 days cells were 
transferred to fresh medium containing 100U/mL IL-2. Cells were employed in flow 
adhesion experiments after 7-8 days (II.9.2). 
 
II.6.6 Isolation of monocytes 
Monocytic cells were isolated from PBMC (0) via depletion of non-monocytic cells. By 
use of the Monocyte Isolation Kit II (containing a cocktail of biotin-conjugated antibodies 
against CD3, CD7, CD16, CD19, CD56, CD123 and CD235a (Glycophorin A), as well as 
αbiotin MicroBeads) and the autoMacs™ device (Miltenyi Biotec, Bergisch-Gladbach, 
Germany) according to the recommended protocol, monocytes were isolated by negative 
selection. 
 
II.6.7 Isolation of neutrophils 
After Ficoll-hypague density gradient centrifugation of venous blood (0) the pellet contains 
neutrophils and erythrocytes. In order to remove erythrocytes, the pellet is resuspended in 
~ 20 mL erythrocyte lysis buffer and incubated RT for 5 min. Cells were washed with PBS 
and kept on ice until further use. 
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Erythrocyte lysis buffer: 155 mM NH4Cl  
 10 mM KHCO3  
 0.1 mM EDTA  
 pH = 7.3 
 
 
II.7 RNA and DNA techniques 
II.7.1 Transformation of E. coli 
E. coli (strain DH5α) were cultured in LB medium at 37°C with vigorous shaking. For 
growth on solid media, a bacteria suspension was spread on a LB agar plate or a single 
bacteria colony was inoculated to achieve single colony growth. The LB plates were 
incubated inverted o.n. at 37°C. For culturing of bacteria transformed with a plasmid 
conferring antibiotic resistance, growth medium was supplemented with the appropriate 
antibiotic. For long-term storage of bacteria at -80°C, LB medium was supplemented with 
glycerol to a final concentration of 15% (v/v). All solutions used for bacteria work were 
autoclaved or filter-sterilized. 
 
Bacteria growth medium 
Bacteria growth medium was autoclaved for 20 min at 121°C. LB agar medium was 
allowed to cool to 50°C before addition of antibiotics. 
 
LB medium: 0.5% (w/v) yeast extract, 
 1% (w/v) peptone 140, 
 1% (w/v) NaCl 
LB agar medium: LB medium with 1.4% (w/v) agar 
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Preparation of heat-shock competent E. coli 
DH5α cells were prepared mainly as described (Chung et al. 1989). 5 mL LB 
medium were inoculated with DH5α and incubated on at 37°C shaking. Then 100 mL LB 
medium were incubated with 750 µL of the o.n. culture for 1 to 2 h at 37°C until the 
optical density at 600 nm (OD600) was approximately 0.4, indicating the early exponential 
growth phase. OD600 was measured in a spectrophotometer with pure medium as reference. 
The culture was centrifuged (10 min/3000 g/4°C), and the pellet was resuspended in 10 mL 
ice-cold TSS buffer. 500 µL aliquots were frozen immediately in liquid nitrogen and stored 
at -80°C. 
 
TSS buffer: 10% (w/v) polyethyleneglycol (PEG) 8000 (Promega) 
 
5% (v/v) DMSO 
 
20 mM MgCl2 
 
in 1x LB medium (II.7.1)  
 
Heat-shock transformation of competent E. coli 
100 µl thawed competent E. coli were gently mixed with 1-5 ng of plasmid DNA, and 
incubated for 30 min on ice. The bacteria were heatshock treated for 90 sec in a 42°C 
waterbath, and then incubated for 2 min on ice. After addition of 900 µL LB medium, the 
bacteria were incubated for 1 h at 37°C with gently shaking. The bacteria were spread on 
selective LB agar plates and incubated on at 37°C to select for transformed bacteria. 
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II.7.2 Plasmids 
 
pcDNA3.1 Invitrogen  
pcDNA3.1/CXCR1 (UMR cDNA Resource Center, Rolla, MO, USA) 
pcDNA3.1/CXCR2 (UMR cDNA Resource Center) 
pcDNA3.1/CXCR3 
pcDNA3.1/his-CD74 
(UMR cDNA Resource Center)    
(UMR cDNA Resource Center) 
pSG5 Stratagene, La Jolla, CA 
pSG5/YB-1 provided by Dr. Peter Mertens (Department of 
Nephrology and Clinical Immunology, UK Aachen, 
RWTH Aachen University, Aachen, Germany) 
H1.Empty lentiviral expression vector RRl-cPPt-H1.PreSIN 
(Seppen et al. 2002) containing the H1 instead of the 
cytomegalovirus (CMV) promoter  
H1.shYB-1 RRl-cPPt-H1.PreSIN containing the H1 promoter and a 
YB-1 siRNA (kindly provided by Dr. Erik A. Biessen, 
Division of Biopharmaceuticals, Leiden Amsterdam 
Center for Drug Research, Leiden University, The 
Netherlands) 
pGL3 luciferase reporter vector (Promega) 
pGL3/RANTES pGL3 containing the RANTES promoter (Ute 
Raffetseder, Department of Nephrology and Clinical 
Immunology, UK Aachen) 
pGL3/-168 containing the truncated RANTES promoter lacking 
the Y-box  (generated by PCR of a -974 nucleotide 
RANTES 5’ upstream fragment based on previously 
described pGL3-based plasmid constructs (pGL3; 
Promega, Madison, WI) (Fessele et al. 2001) 
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II.7.3 Miniprep: Small-scale purification of plasmid DNA 
Plasmid DNA was purified from a bacteria culture by alkaline lysis as described 
(Sambrook and Russell 2001 ) mL o.n. culture was centrifuged (1 min/7000 g/RT) and the 
pellet was resuspended in 100 µL buffer 1. For lysis of the bacteria, 200 µL of buffer 2 was 
added followed by gently mixing and 5 min incubation at RT. The mixture was neutralized 
by 200 µL ice-cold buffer 3, gently mixed, and incubated for 5 min at -20°C. The 
suspension was spun down (20 min/20000 g/RT) to remove proteins, cell debris and 
chromosomal DNA. The supernatant with plasmid DNA was transferred to a new 
eppendorf tube mixed with 500 µL isopropanol and centrifuged (20 min/20000 g/RT). The 
pellet with plasmid DNA was washed with 70% (v/v) ethanol, air dried and resuspended in 
50 µL 10 mM Tris-HCl, pH 8.5.  
 
Buffer 1: 50 mM glucose 
 25 mM Tris-HCl, pH 8.0 
 10 mM EDTA, pH 8.0  
 
 
Buffer 2: 200 mM NaOH 
 1% (w/v) SDS 
 
Buffer 3: 3 M potassium acetate, pH 5.5 
 
II.7.4 Midiprep and Maxiprep: Large-scale purification of 
plasmid DNA 
Large-scale purification of plasmid DNA from bacteria o.n. culture was performed using 
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the Qiagen Plasmid Midi or Maxi Kit™ (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. 
 
II.7.5 Restriction endonuclease digestion of DNA 
Restriction endonucleases (MBI Fermentas, Ontario, Canada) were used to digest double-
stranded DNA for analytical purposes. Restriction endonucleases recognize specific 
palindromic sequences and cleave a phosphodiester bond at each strand at that sequence. 
Restriction endonuclease digestion of DNA for analytical purpose was done according to 
the manufacturer’s instructions. 0.2-1 µg DNA were digested with 5-10 U restriction 
enzyme in a volume of 20 µL. Digests were incubated for 1 h at 37°C or as recommended 
by the supplier. Reaction buffers were supplied by the manufacturer. 
 
II.7.6 Agarose gel electrophoresis 
Separation of DNA fragments from digest was done by agarose gel electrophoresis. The 
negatively charged DNA fragments migrate towards the anode in an electric field at a rate 
determined by the size. DNA samples were diluted with DNA loading buffer and separated 
on a 1-2% (w/v) agarose gel dissolved in TAE electrophoresis buffer containing 0.1 µg/mL 
ethidium bromide. After electrophoresis at 110 V, the DNA was visualized on a UV light 
transilluminator and photographed for documentation. 
 
DNA loading buffer (6x): 30% (v/v) glycerol 
 6 mM EDTA 
 0.25% (w/v) bromophenol blue 
 0.25% (w/v) xylenecyanol 
 
TAE electrophoresis buffer (1x): 40 mM Tris-acetate 
 1 mM EDTA 
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II.7.7 Quantification of DNA and RNA 
DNA and RNA concentration was determined by measuring the absorbance at 260 nm 
(A260) in a spectrophotometer using a quartz cuvette. For double-stranded DNA an A260 = 1 
corresponds to 50 µg DNA/mL, and for RNA an A260=1 corresponds to 40 µg RNA/mL. 
The absorbance at 280 nm was also measured to estimate DNA and RNA purity. Pure 
DNA or RNA has an A260/A280 ratio of 1.8-2.0 at pH 7.0. 
 
II.7.8 Sequencing of DNA 
The sequence of DNA constructs were screened by a commercial sequencing service 
(MWG Biotech, Martinsried, Germany) and the sequence data were verified on the basis of 
the corresponding electropherogram. 
 
II.7.9 Transfection of eukaryotic cells 
Stable transfection of L1.2 and HEK-293 cells 
L1.2 cells stably expressing the chemokine receptors CXCR1, CXCR2 or CXCR3 and 
HEK-293 (HEK) cells stably expressing CXCR2 were generated by electroporation with 
subsequent selection: 107 L1.2 or HEK cells growing in log phase (passaged the day before 
transfection) were transfected with 10 µg plasmid DNA (pcDNA3.1, pcDNA3.1/CXCR1, 
pcDNA3.1/CXCR2 or pcDNA3.1/CXCR3) using the gene-pulser II electroporator (Bio-
Rad) with the parameters 260 V, 975 µF, 200 Ω. After 48 hours cultivation in growth 
medium, transfected cells were selected with G418 sulfate at 800 µg/ml. G418-resistent 
cells were subcloned by limiting dilution in 96-well plates with flat bottom and clones 
were analyzed by flow cytometry with the mAbs αCXCR1, αCXCR3, αCXCR2-FITC and 
the respective isotype controls. 
 
Transient transfection of Jurkat T cells, VSMC, HCASMC and L1.2 cells 
2 × 106 VSMC and HCASMC (grown until 80% confluence) were transfected with 3 µg 
pSG5/YB-1 or vector control using the HAoSMC Nucleofector Kit and the Nucleofector™ 
device (Amaxa) according to the manufacturer’s manual. Transfected VSMC were 
cultivated in 25 cm² flasks for 24 h in non-selection medium and further processed for gene 
expression determination via real time-polymerase chain reaction (PCR) (II.7.10). 
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HCASMC were cultured in 35 mm² dishes for 24 h to 48 h and employed in a flow 
adhesion assay (II.9.2). The same system was employed for the transfection of Jurkat T 
cells with the expression vector pcDNA3.1/CXCR2. Here, the Cell Line Nucleofector Kit 
V was used. Cells were split to a concentration of 1 × 106 cells per mL one day before the 
transfection. 
 
II.7.10 Quantitative real time-PCR 
To determine IL-8, Gro-α, YB-1 or RANTES gene expression, a real time-PCR was 
performed using the QuantiTect Kit with SYBRGreen™ (Qiagen) and specific primers 
according to manufacturer’s protocol. The real time-PCR technique is based on the ability 
of the fluorescent dye SYBRGreen to bind to double-stranded DNA, i.e. the increase in 
double-stranded DNA can be directly detected. Thus, the increase of fluorescence over the 
reaction time can be associated with the employed mRNA concentration. 
RNA from HUVEC, HAoEC, or HVSMC was isolated using the RNeasy Mini Kit™ 
(Qiagen) following digestion of genomic DNA using the RNase-free DNase set (Qiagen) 
according to the manufacturer’s protocol. After determination of the RNA amount (I.5.6), 
up to 1 µg messenger RNA (mRNA) was reverse-transcribed with the Omniscript RT Kit 
(Qiagen) using oligo-dT primers. RNA was reverse-transcribed into cDNA at 37°C for 1 h. 
100 ng cDNA were assessed in the real time-PCR reaction. The housekeeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a reference gene. 
Reverse transcription: 2 µL 10x reverse transcription buffer 
 2 µL dNTP mix (5 mM each) 
 2 µL 10 µM oligo-dT primer (MWG Biotech) 
 1 µL RNase inhibitor (10 U/µL) 
 1 µL Omniscript reverse transcriptase 
 1 µg template RNA 
 H2O to a final volume of 20 µL 
 
Real time-PCR 2 µL cDNA or H2O 
II  Material and Methods 
 31 
 20 µL 2x QuantiTect SYBR Green PCR Master Mix 
 forward primer to a final concentration of 0.5 µM 
 reverse primer to a final concentration of 0.5 µM 
 RNase free water to final volume 40 µL 
 
Real time-PCR Program:  
1. Initial activation 95°C, 15 min 
2. Denaturation  94°C, 15 sec 
3. Annealing  55°C, 30 sec  
4. Extension  72°C, 30 sec 
5. Plate read  
 
The relative mRNA expression is estimated as follows: 
∆Ct  = Ct(target) - Ct(reference) 
∆∆Ct  = ∆Ct - ∆Ct(target control) 
relative mRNA expression:    Ct)(2 ∆∆−  
Ct: Cycle number at which the fluorescence intensity exceeds a determined threshold 
Primers for real time-PCR: 
 
YB-1: 5'-CACCTTACTACATGCGGAGACCT-3',  
 5'-TTGTCAGCACCCTCCATCACT-3' 
RANTES:  5'-TTGCCTGTTTCTGCTTGCTC-3',  
 5'-TGTAACTGCTGCTGTGTGGT-3' 
GAPDH:  5′-GCCTCAAGATCATCAGC-3′;  
 5′-ACCACTGACACGTTGGC-3′  
 
 
× 45 
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GRO-α:  5′-AGGGAATTCACCCCAAGAAC-3′,  
 5′-TAACTATGGGGGATGCAGGA-3′  
IL-8:  5′-TCTGCAGCTCTGTGTGAAGG-3′,  
 5′-AATTTCTGTGTTGGCGCAGT-3′  
 
II.8 Protein assays 
II.8.1 Electrophoretic mobility shift assay (EMSA) 
For preparation of nuclear extracts, HCASMC were lysed in ice-cold hypotonic buffer. 
Sequential centrifugation at 1000 g for 10 min and 5000 g for 5 min was performed at 4oC 
to pellet nuclei, yielded by addition of high salt extraction buffer for 20 min on ice. After 
final centrifugation at 15000 g, supernatant containing nuclear proteins was collected and 
concentrations determined by Bio-Rad protein assay using bovine serum albumin as 
standard. Extracts were stored at -80°C until performance of EMSA.  
 
Recombinant YB-1 was prepared from a pRSET vector (Invitrogen) containing an 
insert encoding for a hexahistidine T7 epitope-YB-1 fusion protein (Mertens et al. 1998). 
Synthetic DNA-probes corresponding to the sense as well as antisense strands of the 
RANTES promoter sequences -204/-173 were end-labeled by means of the Biotin 3’ End 
DNA-labeling Kit™ (Pierce, Rockford, IL, USA), which uses terminal deoxynucleotidyl 
transferase to catalyze nontemplate-directed nucleotide incorporation onto the 3’-OH end 
of DNA. Double-stranded DNA was generated by mixing equal amounts of labeled 
complementary oligos and incubating the mixture for 1 h at room temperature. The 
nucleotide sequences were:  
 
5’-CCGGTACCCATTGGTGCTTGGTCAAAGAGGAAACTGATGAGCTCACTCAG 
ATCTGC-3’ (sense) 
5’-GCAGATCTGAGTGAGCTCATCAGTTTCCTCTTTGACCAAGCACCAATGGGT 
ACCGG-3’ (antisense) 
 
Biotin-labeled DNA was incubated with affinity-purified recombinant YB-1 protein 
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(II.4) (by Ute Raffetseder, UK Aachen) or nuclear cell extract for 20 min on ice, subjected 
to gel electrophoresis (II.7.6) on native 6% polyacrylamide gels, and transferred to nylon 
membranes. Bands were visualized by streptavidin-HRP conjugate and chemiluminescent 
substrate (LightShift chemiluminescent EMSA kit, Pierce). For supershift analyses, 
peptide-derived affinity-purified rabbit αYB-1 antibody (peptide antibody against amino 
acids 185-206) was incubated with nuclear proteins 12 h prior to addition of probes. The 
binding reaction was as above and samples were subjected to electrophoresis in 6% 
polyacrylamide gels. 
 
Lysis buffer: 10 mM HEPES (pH 7.9) 
 1.5 mM MgCl2  
 10 mM KCl  
 0.5 mM DTT 
 supplemented with a proteinase inhibitor cocktail (Complete Mini, 
Roche, Mannheim, Germany)  
 
Extraction buffer: 20 mM HEPES/KOH (pH 7.9) 
 1.5 mM MgCl2   
 420 mM NaCl  
 0.2 mM EDTA  
 25% glycerol 
 
II.8.2 Enzyme-linked immunosorbant assay (ELISA) 
The IL-8 and RANTES concentrations in the supernatants of stimulated and unstimulated 
HAoEC or YB-1 overexpressing SMCs were detected via ELISA. HAoEC were incubated 
with MIF (50 ng/mL) or TNF-α (100 U/mL) for 2 h at 37°C, and the levels of IL-8 in the 
supernatant were quantified using the Quantikine ELISA Immunoassay (R&D Systems) 
(Fig.II.1). RANTES secretion by YB-1-transfected SMCs (0) was also determined via a 
Quantikine ELISA Kit (R&D Systems). These Kits contained a 96 well polystyrene 
microplate (12 strips of 8 wells) coated with mAbs against IL-8 or RANTES, which 
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immobilized the proteins on the well surface. After binding of a HRP-conjugated detection 
pAb and reaction with a substrate, a color change according to the protein content was 
measured at a wavelength of 450 nm with an ELISA reader and evaluated via XFluor™ 
Software (Tecan, Crailsheim, Germany). 
 
 
 
Fig.II.1: ELISA. From left to right: mAbs specific for e.g. IL-8 coated to polystyrene microplate bind to the 
IL-8 proteins from cell supernatants and immobilize the protein on the microplate. Secondary HRP-
conjugated αIL-8-Abs bind to the immobilized protein and oxidize a substrate resulting in a color change of 
the substrate solution, which can be detected and evaluated by an ELISA-reader. 
 
 
II.8.3 Flow cytometry 
Flow cytometry can be used to just analyze cells by their size, granularity and protein 
expression (by e.g. FITC-conjugated detection Abs) or to sort cell populations (FACS = 
Fluorescent activated cell sorting). In a buffer stream one cell at a time passes by an argon 
laser, which excites fluorescently labeled cells. Measurements of the size (forward scatter) 
and granularity (sideward scatter) are independent from the fluorescence signal.  
Measurement of fluorescence intensity using fluorescence labeled Abs was done to 
examine the expression of chemokine receptors on the cell surface or the activation of the 
αLβ2 integrin activation (II.9.3). The results were displayed as histograms showing the 
logarithmic distribution of the fluorescence intensity or as diagrams demonstrating the 
change in mean fluorescence intensity (MFI). For receptor expression determination, 1 × 
105 cells were resuspended in PBS with specific Ab or IgG isotype control (10 µg/mL) and 
incubated for 30 min on ice. After washing, the cells were incubated with a FITC-
conjugated detection Ab (10 µg/mL) for 30 min on ice. The cells were washed and 
analyzed immediately by flow cytometry in a FACSCalibur (BD Biosciences). 
The change of MFI as a cause of chemokine-mediated Ca2+ influx (II.9.4) was 
measured with the FACSAria System and evaluated with FlowJo Software (BD 
Biosciences). 
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II.8.4 Coimmunoprecipitation  
For extraction and precipitation of the CXCR2/CD74 complex, L1.2 cells expressing 
human recombinant human CXCR2 (II.7.9) and CD74 as well as untransfected cells were 
washed with ice-cold PBS and resuspended in nondenaturing lysis buffer to a final 
concentration of 5 × 106 cells/mL. After 30 min incubation on ice, cell debris was spun 
down at 14500 × g for 20 min. The clear supernatants were incubated with 30 µL protein 
A-sepharose beads for 1 h on a roller mixer. After centrifugation of the beads the 
supernatants were incubated with 2.5 µg αCXCR2 antibody (RII115) or the respective 
isotype control for 1 h. Subsequently 30 µL of pre-blocked protein G-sepharose beads (2 h 
incubation with 2.5% BSA and 2.5% Roti-Block™ (BioRad, Hercules, CA, USA) at 4˚C) 
were added to the supernatants and incubated over night. All incubations were carried out 
at 4˚C. Precipitates were washed three times with wash buffer and once with PBS. Proteins 
were eluted with 60 µL hot elution buffer. 
The pull down of the MIF/CXCR2 complex was performed similarly: 5 × 106 HEK 
cells stably expressing CXCR2 and control transfectants (0) were incubated with biotin-
MIF (1µg) for 30 min at 4˚C, spun down and lyzed with 1 mL lysis buffer. After 
centrifugation of cell debris, lysates were incubated with 100 µl Dynalbeads M280 
Streptavidin (10 mg/ml) (Invitrogen) for 30 min at 4˚C. The Dynalbeads were collected by 
Dynal magnetic partical concentrator. The beads were washed three times with 1:5 diluted 
lysis buffer. The precipitated proteins were eluted by boiling the beads in SDS loading 
buffer. 
 
 
 
Non-denaturing lysis buffer: 1% (w/v) Triton X-100 
 1% (w/v) (CHAPSO) (Calbiochem)  
 50 mM Tris-HCl (pH 7.4) 
 100 mM NaCl 
 15 mM EGTA 
 0.02% (w/v) sodium azide  
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 10 mM iodoacetamide 
 supplemented with a proteinase inhibitor cocktail 
(Complete Mini, Roche, Mannheim, Germany) 
 
 
Wash buffer:  0.1% (w/v) Triton X-100 
 50 mM Tris-HCl (pH 7.4)  
 100 mM NaCl 
 15 mM EGTA  
 0.02% (w/v) sodium azide 
 
Elution buffer:  1% (w/v) SDS 
 100 mM Tris-HCl (pH 7.4)  
 10 mM dithiotreitol (DTT) 
 
 
II.8.5 SDS-polyacrylamide gel electrophoresis (PAGE) 
After immunoprecipitation of CXCR2, the protein and co-immunoprecipitated CD74 were 
analyzed by SDS-PAGE. SDS binds to polypeptides resulting in a negative charge directly 
proportional to protein size. Protein samples were first concentrated in a stacking gel 
before migrating into the resolving gel. Electrophoresis was carried out at 200 V. The 
resolving gel was further analyzed by western blotting (II.8.6) 
Resolving gel: 12% (w/v) acrylamide/Bis 
 375 mM Tris-HCl, pH 8.8 
 0.1% (w/v) SDS 
 0.1% (w/v) ammonium persulfate 
 0.1% (v/v) TEMED 
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Stacking gel:  5% (w/v) acrylamide/Bis 
 125 mM Tris-HCl, pH 6.8 
 0.1% (w/v) SDS (sodium-dodecylsulfate) 
 0.1% (w/v) ammonium persulfate 
 0.1% (v/v) TEMED 
 
 
Electrophoresis buffer:  (10x) 250 mM Tris base 
 1.92 M glycine 
 1% (w/v) SDS 
 
 
 
II.8.6 Western blot analysis 
Separated proteins from a SDS-PAGE (II.8.6) were transferred to a nitrocellulose 
membrane and detected using specific primary Abs and HRP-conjugated secondary Ab. 
The proteins were transferred from the gel to the nitrocellulose membrane (Hybond-ECL, 
Amersham Biosciences, Uppsala, Sweden), at 90 V for 1 hour in ice-cold blotting buffer. 
Nonspecific binding sites on the membrane were blocked with 5% (w/v) nonfat milk in 
TBS for 1 hour at RT. Thereafter, the membrane was incubated with a primary Ab diluted 
in blocking buffer for 1 hour at RT or o.n. at 4°C. After 3 times washing with TBS/0.05% 
(v/v) Tween, the membrane was incubated with a HRP-conjugated secondary Ab diluted in 
TBS for 1 hour at RT or on at 4°C. In the presence of hydrogen peroxide (H2O2) the 
protein-bound HRP converted the substrate ECL (enhanced chemiluminescence) (Pierce, 
Rockford, IL, USA) to a light-emitting carbonyl, and the specific protein bands were 
visualized via exposure to an autoradiografic film (Kodak, Rochester, NY,USA). 
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II.8.7 Histochemistry  
Serial tissue sections of the left common carotid artery (II.10.1) of Apoe-/-, Met-RANTES-
treated Apoe-/- and Apoe-/-/Ccr5-/- mice were stained according to MOVAT’s pentachrome 
staining. After paraffin removal by dipping the cover slides with the tissue sections in 
baths of xylene and graded alcohols are stained with the following dyes. Cover slides are 
washed with acetic ethanol and water in between each staining step. 
 
1. Staining with Alcian blue (Sigma) for 20 min to visualize mucins and 
glycosaminoglycans: 
Staining solution: Alcian blue 1% (w/v) 
 in acetic acid (1%)  
 
2. Staining with orcein (Merck) and haematoxylin for 30 min to visualize elastic fibers 
and cell nuclei: 
Staining solutions:   
A: orcein 1% (w/v) 
 in ethanol (70%)  
 acetic acid (25%) 0.5% (v/v) 
   
B: haematoxylin   15% (w/v) 
 in  ethanol (100%)  
 
  
Blotting buffer (1x) 25 mM Tris base 
 192 mM glycine 
 10% (v/v) methanol 
 0.005% (w/v) SDS 
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C: iron(III)-chloride 10% (w/v) 
 in water   
 
  
D: iodine 1% (w/v) 
 potassium iodide 2% (w/v) 
 in water  
Two volumes of solution B are mixed with one volume of solutions A, C, and D. 
3. Staining with Brilliant Crocein Scarlet MOO (Sigma) for 10 min: 
Staining solutions:   
Solution A:  Brilliant Crocein Scarlet  0.1% (w/v) 
 in glacial acetic acid  
 
  
Solution B: acid fuchsin 0.1% (w/v) 
 In acetic acid  (0.5% v/v) 
Working solution: volumes of A and 1 volume of B 
 
4. Staining with saffron for 15 min: 
Staining solution: saffron 6% (w/v) 
 in ethanol (100%)  
After staining, the sections are washed in ethanol and xylol to remove water and 
covered with Entellan (Merck). 
Stained tissue:   
Nuclei dark violet/black 
Cytoplasm pink/red 
Elastic fibers violet/black 
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Collagen yellow/yellow-green 
Extracell. matrix blue/blue-green 
Muscle red 
 
II.8.8 Immunofluorescence 
Confluent HAoEC and CHO-ICAM-1 cells grown on glass slides were incubated with MIF 
(50 ng/mL) for 2 h at 37˚C. After washing with phosphate-buffered saline (PBS) and 
fixation with 2% paraformaldehyde/PBS (PFA), cells were stained for surface-bound MIF 
using the polyclonal rabbit MIF antibody Ka565 (1:500) followed by a FITC-conjugated 
goat αrabbit Ab, and mounted with Vectashield containing DAPI (Vector Labs, 
Burlingame, CA). 
Tissue sections of aortic roots (II.10.2) or the left common carotid artery (II.10.1) of 
Apoe-/- mice were stained for CD3, MOMA-2, α-SMA, Mac2, RANTES or  
YB-1. For detection, Cy3- or FITC-conjugated secondary Abs were used (II.5.5). The 
relative macrophage or T cell content was determined by quantifying the area positive for 
Mac2 or CD3. Images were recorded with a Leica DMLB fluorescence microscope and 
charge couble device (CCD) camera. 
 
II.9 Functional assays 
II.9.1 Luciferase reporter assay 
The Promega luciferase assay system (Mannheim, Germany) was employed in order to 
quantitatively analyze YB-1-triggered activation of the RANTES promoter. HCASMC and 
RAW264.7 cells were transfected with the reporter vector pGL3/RANTES (II.7.2, II.7.9) 
containing the full length RANTES promoter or the truncated promoter (pGL3/-168) 
upstream of a modified firefly luciferase gene. Moreover, the cells were co-transfected 
with the YB-1 overexpression vector pSG5/YB-1, or promoter activation by endogenous 
YB-1 was attenuated by means of short hairpin RNA (shRNA) generated by pSuperduper 
plasmid (OligoEngine, Seattle, WA, USA) with the sequence 5'-GGTCATCGCAACGAA 
GGTTTT-3' introduced as a tail-to-tail tandem repeat corresponding to base pairs (bps) 
285 to 305 of the human YB-1 coding sequence (accession nr. J03827) (provided by Ute 
Raffetseder). As indicated, human IFN-γ (100 U/mL) was added to the cells. YB-1-
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triggered luciferase expression was measured 24 h after transfection in a single tube 
luminometer (Sirius, Berthold Detection Systems, Pforzheim, Germany). Results were 
calculated as fold-changes relative to luciferase activity measured with pGL3 plasmid 
without promoter. 
 
II.9.2 Parallel plate flow chamber adhesion assay 
MonoMac6, Jurkat T cells and Jurkat cells transiently expressing CXCR2, L1.2, and 
primary monocyte or T cell arrest on CHO-ICAM-1monolayers, HAoEC, SVEC, 
HCASMC or VCAM-1.Fc was analyzed in a parallel wall chamber under laminar flow 
condition. CHO-ICAM-1 cells, HAoEC, SVEC, pSG5/YB-1 transfected or untransfected 
HCASMC were grown to confluence in 35 mm dishes or plates coated with VCAM-1.Fc 
(0.5 µg/mL) were pre-incubated with MIF (50 ng/mL), IL-8 (10 ng/mL), IP-10 (500 
ng/mL), SDF-1α (100 ng/mL) or control buffer for 2 h at 37˚C. Leukocytes were directly 
incubated with MIF (250 ng/mL), IL-8 (100 ng/mL) or SDF-1α (100 ng/mL) as indicated. 
The arrest of L1.2 transfectants on SVEC monolayers was assessed in the presence or 
absence of the CXCR4 antagonist AMD3465 (10 µM). Monocytes and T cells (2.5-
5×105/mL) labeled with calcein-AM (Molecular Probes/Invitrogen, Paisley, UK) in HH 
buffer  (II.2) were pretreated with PTX (0.5 µg/mL) for 2 h or with blocking mAbs against 
β2, α4, CD74, CXCR4 (all 10 µg/mL), CXCR1 (30 µg/mL), CXCR2 (3 µg/mL), or 
isotype-matched control IgG at corresponding concentrations for 30 min and perfused at 
1.5 dyn/cm2. In particular experiments the HAoEC monolayers were incubated with 
blocking Abs against Gro-α, IL-8, and MIF. In certain approaches HCASMC were 
incubated with the RANTES receptor antagonist Met-RANTES. After 5 min, the number 
of adherent cells was quantified in multiple fields (0.24 mm2 each, >10 per treatment) by 
analysis of images recorded with a long integration 3CCD video camera (JVC, Japan) 
using AnalySIS software (Soft Imaging System, Münster, Germany). For analysis of arrest 
on CHO-ICAM-1 cells, background adhesion to vector-transfected CHO cells was 
subtracted. 
 
II.9.3 αLβ2 integrin activation assay 
MonoMac6 cells or primary monocytes (5 × 105 cells/mL) were stimulated with MIF (50 
ng/mL) in assay buffer without Ca2+/Mg2+ at 37˚C for indicated periods. Incubation of cells 
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without MIF for 30 min served as negative control. As a positive control, cells were 
incubated with 3 mM Mg2+ and 1 mM EGTA (ethylene glycol bis(2-aminoethyl-ether)-
N,N,N'N'-tetraacetic acid). Cells were fixed with 2% PFA, reacted with 327C (10 µg/mL) 
and αmouse-IgG FITC conjugate and analyzed by flow cytometry. Activation of αLβ2 was 
reported by the increase in MFI (Shamri et al. 2005). 
 
II.9.4 Calcium mobilization assay 
The activation of cells due chemokine/GPCR interaction causes a rapid influx of Ca2+ and 
the release of Ca2+ from the endoplasmic reticulum. This calcium mobilization can be 
visualized by the fluorophore Fluo-4. Fluo-4 AM (Molecular Probes, Eugene, OR, USA) is 
a calcium indicator, which can be loaded into cells. After the uptake, the lipophilic 
acetoxymethyl group is cleaved off the originally hydrophilic fluorophore by cellular 
esterases. Upon binding to cytosolic Ca2+, Fluo-4 exhibits an increase in MFI, which can 
be detected by flow cytometry (II.8.3). 
 
Neutrophils and L1.2/CXCR2 transfectants were labeled with 0.9 µM Fluo-4 AM in 
assay buffer for 45 min at 37 ˚C. Subsequently cells were once washed with assay buffer 
and resuspended to a final concentration of 2x106/ml - 500 µl per sample. Calcium 
mobilization in respond to a stimulus, e.g. MIF was detected via the FACSAria. Samples 
were homogenized by passing them through pre-separation filters (Miltenyi) just prior to 
the FACS measurement. Baseline fluorescence was recorded for 10 sec. Then the stimulus 
was added to the cells and the change in MFI was recorded for another 2 min. For 
determining desensitization, a second stimulus was given after the measurement and the 
MFI was recorded another 2 min. 
 
Assay buffer: 4.6 mM KCl  
 1 mM CaCl2 
 130 mM NaCl  
 5 mM glucose  
 20 mM HEPES 
 0.1% human serum albumin 
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II.10 Animal experiments 
II.10.1 Mouse model of arterial wire-injury and lentiviral 
transduction 
Apoe-/- mice were fed a Western type diet (containing 0.25% cholesterol and 15% 
cacaobutter, SDS, Sussex, UK) from 1 week prior to surgery and throughout the 
experiment. Transluminal wire injury of the left common carotid artery was performed as 
described (Lindner et al. 1993; Schober et al. 2002; Schober et al. 2003) (Fig.II.2). A 
0.014-in flexible angioplasty guidewire was advanced into the common carotid artery via 
the left internal carotid artery and endothelial denudation was achieved by three rotational 
passes. For lentiviral transfer, the lumen of the carotid artery was incubated with the 
H1.shYB-1 or H1.empty (II.7.2) carrying lentivirus solution (1010 i.u./mL) for 15 min. 
directly after wire-injury. Two groups of Apoe-/- mice (n = 6 each) were treated with 
MetRANTES (40 µg 3 times a week) after wire injury and lentiviral transduction. Animals 
were sacrificed at 4 weeks after injury. Starting at the bifurcation serial tissue sections (5 
µm) were obtained from left common carotid arteries. For morphometry, ten sections (each 
50 µm apart) were stained with Movat’s pentachrome (II.8.7), and subjected to planimetric 
analysis (Diskus software, Hilgers, Königswinter, Germany).  
 
 
 
Fig. II.2: Arterial wire-injury.  
A flexible guidwire is introduced into the 
internal carotid artery (ICA) and 
advanced into the common carotid artery 
(CCA). The endothelial denudation is 
achieved by three rotational passes. 
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II.10.2 Mouse model of atherosclerotic disease progression 
Apoe-/- mice (C57BL/6) were fed an atherogenic diet containing 21% fat (Atromin) for 12 
weeks and sacrificed. Subgroups were injected with blocking MIF mAb (NIHIIID.9), 
blocking αSDF-1α mAb (II.5.3), blocking αGro-α antibody (II.5.3), or vehicle/PBS starting 
at 12 weeks of diet and subsequently twice weekly (50µg intraperitoneally (i.p.)) until 
sacrifice at 16 weeks of diet. Hearts were harvested by in situ perfusion fixation with 4% 
PFA. The extent of atherosclerosis was assessed in aortic roots by staining of 5 µm 
transversal sections (3-6/mouse) for lipid deposition with Oil-red-O. After staining with 
Oil-red-O for 30 min, the tissue sections were washed with PBS until the buffer remained 
clear and quantified by computerized image analysis (Diskus software, Hilgers, Aachen, 
Germany). The relative content of macrophages and CD3+ T cells was determined by mAb 
staining for MOMA-2 and CD3 detected by FITC-conjugated secondary antibody (II.8.7). 
Images were recorded with a Leica DMLB fluorescence microscope and CCD camera. 
 
II.10.3 Ex vivo perfusion and intravital microscopy of murine 
carotid arteries 
In order to study the MIF-mediated leukocyte arrest on early atherosclerotic endothelium, 
we performed cell adhesion assays under flow conditions in murine carotid arteries. 
Preparation for ex vivo perfusion of murine carotid arteries was performed as described 
(Huo et al. 2001). Apoe-/-, Mif+/+Ldlr-/- and Mif-/-Ldlr-/- mice were fed an atherogenic diet 
containing 21% fat (0.15% cholesterol, 19.5% casein; Altromin, Germany) for 6 weeks. 
Wild-type Mif+/+ and Mif-/- mice were treated with TNF-α (1 µg) by i.p. injection 4 h 
before perfusion experiments. The common carotid artery and the internal branch were 
ligated and a catheter was inserted through incision of the common carotid artery cranial to 
the suture. Arteries were transferred onto the stage of an Olympus BX51 microscope 
equipped with a saline immersion 20× objective and superfused with PBS at 37°C. 
MonoMac6 cells labeled with calcein-AM were pre-treated with CXCR2, CD74 mAbs or 
isotype control or the artery was perfused with blocking MIF mAb NIHIIID.9 (60 µg/mL) 
for 30 min. Arteries were perfused with monocytic cells (106/mL) in MOPS-buffer at a 
flow rate of 4 µL/min using a syringe pump (GENIE; Kent Scientific Corporation, 
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Litchfield) and adhesive interactions with the vessel wall (arrest, rolling) were recorded by 
stroboscopic epifluorescence illumination (Drelloscop 250; Drello, Mönchengladbach, 
Germany). At 10 min of perfusion, cells not moving for >30 s were defined as firmly 
adherent, and arrest was quantified in all segments of the artery. 
For in vivo microscopy, the left carotid artery was surgically exposed in anesthetized 
mice 4 h after i.p. injection of TNF-α (1 µg/ml) and rhodamin G (100µL 0.02%; Molecular 
Probes) was administered into the lateral tail vein. After 30 min, adhesive interactions of 
labeled leukocytes with the common carotid artery were visualized in situ using a Zeiss 
Axiotech microscope (water immersion objective; Zeiss, Munich, Germany) with a 100 W 
HBO mercury lamp for epi-illumination (Osram, Eichstätt, Germany). The number of cells 
adherent to the artery wall was quantified in at least three fields of observation at 20× 
magnification. 
 
II.10.4 Bone marrow repopulation 
 For bone marrow transplantation femurs and tibias were aseptically removed from donor 
Cxcr2-/- or BALB/c control mice. Marrow cavities were flushed and single cell suspensions 
prepared. Donor cells (3 × 106) were administered by tail vein injection into 6-8 week old 
Mif+/+ or Mif-/- mice 24 h after an ablative dose of whole-body irradiation (2x6 Grays 
(Gy)). 
 
Model of acute inflammation in the peritoneal cavity 
Wildtype C57BL/6 mice reconstituted with Cxcr2+/+ or Cxcr2-/- bone marrow cells were 
injected i.p. with 200 ng MIF in sterile PBS. After 4 h, the peritoneal exudate was 
harvested by an i.p. lavage with sterile PBS. The number of immigrated neutrophils was 
analyzed by quantifying the number of Gr-1+CD115-F4/80- cells by flow cytometry using 
fluorochrome-conjugated mAbs detecting CD115, Gr-1, F4/80 or appropriate IgG isotype 
controls (II.5.2). 
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II.11 Data illustration and statistical analysis  
Graphs display results as mean ± SEM of 3 to 10 independent experiments, if not indicated 
otherwise. To compare data, one-way analysis of variance (ANOVA) and Newman-Keuls 
post-hoc test or an unpaired Student’s t-test with Welch’s correction was performed using 
GraphPad Prism 4. Differences with at least P<0.05 were considered as statistical 
significant. 
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III Results 
 
III.1 The Role of YB-1 in RANTES-mediated 
atherosclerosis 
III.1.1 YB-1 binds to a Y-box in the RANTES promoter  
To detect additional regulatory elements involving YB-1 within the RANTES promoter, its 
sequence was compared with those of the Y-boxes of the MMP-2 and the DNA 
polymerase α gene. A sequence with homologies with known YB-1 binding motifs was 
identified within the proximal RANTES sequence between -204 and -173 base pairs from 
the start codon, containing several matching nucleotides but also an inverted repeat motif 
(Fig. III.1.1). In the preliminary investigation, an electrophoretic mobility shift assay using 
nuclear extracts of HASMC and rYB-1 was performed. The gel electrophoresis revealed 
that YB-1 bound to the biotin-labeled RANTES promoter element (Fig. III.1.2).  
 
 
Fig. III.1.1: YB-1 recognition 
elements in the RANTES 
promoter. Sequence alignment of 
the proximal CCL5/RANTES gene 
promoter with known YB-1 
binding motifs in the MMP-2 and 
DNA-polymerase α (DPA) genes 
revealed similarities of the 
sequence -210/-170 bps with 
known YB-1 binding motifs, that 
are matching nucleotides within 
the Y-box and the presence of a 3’ 
localized inverted repeat motif 
(indicated by arrows). 
 
While recombinant YB-1 bound to the single-stranded proximal sense (SS1) (Fig. 
III.1.2, A, lane 4) and antisense (SS2) promoter region (Fig III.1.2, A, lane 6), no binding 
to a double-stranded DNA probe (DS) was observed (Fig. III.1.2, A, lane 2). Specificity of 
binding was confirmed by inhibition of YB-1 binding to the single stranded antisense 
probe in the presence of homologous competitor DNA (hom.C) at 500-fold molar excess 
(Fig. III.1.2, A, lane 7-9).  Complex formation of the same mobility with the single 
stranded antisense probe was observed when testing nuclear extracts derived from SMC 
(NESMC) (Fig. III.1.2, A, lane 10). Furthermore, the SS2-NESMC complex mobility was 
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supershifted with a YB-1 specific antibody (Fig. III.1.2, B, lane 2), supporting the 
assumption that YB-1 functions in the regulation of RANTES promoter activity. 
 
A                                                                                             B 
 
Fig. III.1.2: Conventional DNA binding studies (EMSA) demonstrated binding of rYB-1 to the 
RANTES promoter element. Synthetic DNA-probes corresponding to the sense as well as antisense 
strands of the RANTES promoter sequences -204/-173 were end-labeled with biotin in order to visualize 
the bands by streptavidin-horseradish peroxidase conjugate and chemiluminescent substrate. Sense (SS1) 
and antisense (SS2) strands of the -204/-173 element were preferentially bound by YB-1 as compared to 
the double-stranded probe (DS) (compare lane 2 with lanes 4 and 6, complex indicated by *). Specificity 
of binding was confirmed by diminished bands after inclusion of homologous competitor DNA (homC.) 
(lane 9). With SMC nuclear extract (NESMC) a complex of the same mobility formed with the antisense 
strand (SS2) probe (lane 10). (C) Binding of a YB-1 specifc Ab resulted in a supershift of the SS2/NESMC 
complex (lane 2) while the isotype control did not bind to the complex (lane 3). 
 
III.1.2 The increased expression of YB-1 and RANTES correlate 
in inflammatory SMC 
Because an upregulation of chemokines has been identified in neointimal SMC with a pro-
inflammatory phenotype (Jordan et al. 1997), the expression of YB-1 and RANTES in rat 
SMC isolated from the media and neointima of balloon-injured aortas was determined. 
Indeed, RANTES mRNA expression was markedly increased in neointimal SMC 
compared with medial cells, as determined by quantitative real time-PCR analysis. In 
parallel, the expression of YB-1 mRNA was increased 3- to 4-fold in neointimal versus 
medial rSMC (Fig. III.1.3), suggesting a role for YB-1 in the regulation of RANTES in 
injured or pro-inflammatory SMC.  
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Fig. III.1.3: YB-1 and RANTES expression 
correlated in inflamed rSMC. The expression of 
YB-1 and RANTES in both neointimal and medial 
rat SMC was examined by real time-PCR. Results 
represent two experiments in duplicate. 
 
III.1.3 YB-1 controls the transcriptional activity and protein 
expression of RANTES in HVSMC 
In order to study regulatory effects of YB-1 on RANTES expression in human VSMC, a 
luciferase reporter assay was employed (Fig. III.1.4). Whereas transfection with empty 
vector pGL3 alone had no effect, transfection with a reporter construct harbouring the 
proximal 1014 base pairs (full-length) of the RANTES promoter (pGL3/RANTES) caused 
a moderate increase in luciferase activity (Fig.III.1.4, A). Co-transfection with YB-1 
(pSG5/YB-1) and pGL3/RANTES led to a significant induction of luciferase activity in 
hSMC. The induction by YB-1 was almost completely attenuated in cells co-transfected 
with a plasmid coding for a reporter construct with a truncated RANTES promoter lacking 
the Y-box (pGL3/-168). Conversely, luciferase activity conferred by the full-length 
promoter pGL3/RANTES was significantly inhibited by co-transfection of YB-1 shRNA 
(Fig. III.1.4, B). To determine the efficiency of YB-1 knock-down, a real time-PCR was 
performed with the shRNA transfected cells. An about 50% decrease of YB-1 mRNA was 
achieved by shRNA transfection (Fig. III.1.4, C).  
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Fig. III.1.4: YB-1 induced RANTES promoter activation in human HVSMC. The effect of YB-1 on 
RANTES promoter activation in human SMC was determined using a luciferase reporter assay. (A) HVSMC 
were co-transfected with pSG5/YB-1 to overexpress YB-1 and vector without promoter (pGL3), reporter 
construct with full-length RANTES promoter reporter (pGL3/RANTES) or with truncated promoter (pGL3/-
168). Overexpression of YB-1 increased RANTES promoter activation (*P<0.05, when compared to 
pGL3/RANTES transfected cells). (B) Knock-down of YB-1 by shRNA (shYB-1) significantly reduced 
promoter activity in hSMC. ). Both pGL3/RANTES and pSuperduper co-transfected HVSMC served as 
controls (**P<0.01, when compared to control). (C) Transfection of HVSMC with YB-1 shRNA (shYB-1) 
resulted in a 50% decrease in YB-1mRNA compared to control-transfected cells (*P<0.05, when compared 
to control). 
 
Next the effect of YB-1 transfection (pSG5/YB-1) on RANTES mRNA and protein 
expression was studied by real time-PCR analysis and ELISA. Overexpression of YB-1 
mRNA in transfected hSMC was associated with a marked up-regulation of RANTES 
mRNA levels compared to control cells transfected with empty vector pSG5 (Fig. III.1.5, 
A). Similarly, RANTES protein secretion was significantly increased in HVSMC 
overexpressing YB-1 and inhibited by shRNA knock-down of YB-1 (shYB-1, Fig. III.1.5, 
B).  
As other cells in addition to SMC are involved in atherosclerotic lesion formation, 
the RANTES promoter regulation by Yb-1 was also tested in the murine macrophage cell 
line RAW264.7. In contrast to SMC, the luciferase reporter assay revealed a negative 
effect of YB-1 on RANTES promoter activity (Fig. III.1.6). YB-1 overexpression reduced 
the basal luciferase activity in pGL3/RANTES transfected cells. To stimulate RANTES 
promoter activation the macrophages were stimulated with (100U/mL) IFN-γ. This 
activation was significantly down-regulated by YB-1. 
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Fig.III.1.5: YB-1 induced RANTES expression in HVSMC. (A) RANTES and YB-1 expression in 
HVSMC 48 h after transfection with the YB-1 overexpression vector pSG5/YB-1 was examined via real 
time-PCR. Both RANTES and YB-1 mRNA levels were increased after transfection (*P<0.05, when 
compared with control transfectants). (B) The level of RANTES protein in HVSMC supernatants was 
increased with YB-1 overexpression as determined by ELISA. (C) YB-1 knock-down via shRNA transfer led 
to an attenuated RANTES expression compared to pSuperduper (control) transfected cells. Results represent 
2 independent experiments in duplicate (B and C). 
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Fig. III.1.6: YB-1 inhibited RANTES promoter 
activity in the macrophage cell line RAW264.7. 
A luciferase reporter assay was performed with 
RAW264.7 cells. Cells were transfected with the 
RANTES reporter construct and pSG5 control 
vector or YB-1 overexpression vector pSG5/YB. 
Luciferase activity was measured in those 
transfectants with or without IFN-γ stimulation; 
(*P<0.05, when compared with pSG5/YB-1 
transfected IFN-γ stimulated cells).  
 
III.1.4 YB-1 induces monocyte adhesion by regulating RANTES 
expression in HCASMC 
As RANTES has been established to control monocyte recruitment (von Hundelshausen et 
al. 2001; Schober et al. 2002), the role of YB-1-mediated RANTES expression in 
MonoMac6 cell arrest on coronary artery SMC (HCASMC) was analyzed under flow 
conditions (Fig. III.1.7). Compared to vector-transfected controls, transfection of 
HCASMC monolayers with pSG5/YB-1 to overexpress YB-1 significantly increased 
monocyte arrest. This increase was mediated by YB-1-induced RANTES protein 
expression, as evidenced by the inhibition after pre-treatment of MonoMac6 cells with the 
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RANTES receptor antagonist Met-RANTES. Thus, YB-1-mediated RANTES expression 
supported increased monocyte recruitment. 
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Fig. III.1.7: YB-1-mediated RANTES 
triggered monocyte arrest under shear flow. 
HCASMC were transfected with the pSG5/YB-1 
and grown in 35 mm² dishes until confluence. 
The cell monolayers were perfused with calcein 
AM-labeled MonoMac6 cells at 1.5 dyne/cm2. 
Adherent MonoMac6 cells were counted after 2 
min of perfusion; (*P<0.05, when compared to 
control transfectants or Met-RANTES treated 
CASMC). 
 
III.1.5 Knock-down of YB-1 protects against neointima 
formation 
Because YB-1 and RANTES mRNA levels are up-regulated in inflammatory neointimal 
SMC (Fig. III.1.3), the next aim was to investigate the role of YB-1 in atherosclerotic 
lesion formation. Therefore an in vivo mouse model of accelerated atherosclerosis was 
employed. Carotid arteries of Apoe-/- (Ccr5+/+), Met-RANTES-treated Apoe-/- and Ccr5-/-
/Apoe-/- mice were luminally transfected with lentiviral shRNA targeting YB-1 or empty 
vector immediately after wire-induced endothelial denudation injury (performed by Ilze 
Bot, Institute of Biopharmaceutics, Leiden University, The Netherlands). Lentiviral 
shRNA transfer led to an approximately 2.5-fold decrease of YB-1 expression in Apoe-/- 
mice as revealed by immunofluorescence (Fig. III.1.8 and Fig. III.1.9). The expression of 
YB-1 and RANTES was colocalized in neointimal cells but also in medial cells of carotid 
arteries after injury, and lesional RANTES expression was almost completely abolished 
after knock-down of YB-1 in H1.shYB-1-treated arteries (Fig. III.1.8, A). Of note, YB-1 in 
vascular lesions was predominantly expressed in colocalization with α-SMA+ SMC (Fig. 
III.1.8, B), but not with Mac-2+ macrophages (Fig. III.1.8, C). 
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Fig. III.8: YB-1 colocalized with 
RANTES and the SMC marker 
α-SMA in lesions of murine 
carotid arteries. Serial sections of 
control and H1.shYB-1-treated 
carotid arteries were stained for 
YB-1 and RANTES, α-SMA or 
Mac-2.  
(A) Double immunofluorescence 
staining for YB-1 and RANTES 
revealed their co-expression in the 
neointima of control (H1.empty) 
carotid arteries (arrows).  
(B) Doublestaining for YB-1 and 
α-SMA demonstrated a strong  
YB-1 expression in medial (arrow) 
area of control transfected carotid 
arteries, as well as in the 
neointimal area of untransfected 
vessels (control, arrow).  
(C) No relevant colocalization of 
YB-1 with the macrophage marker 
Mac-2 was found in the plaque area 
(C; arrow). YB-1 and RANTES 
expression was markedly reduced 
in H1.shYB-1-treated arteries (A-
C). 
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Analysis of the lesional areas in the carotid artery after 4 weeks revealed a significant 
reduction in the neointima and media in YB-1 shRNA (H1.shYB-1) in comparison to 
control (H1.empty)-treated Apoe-/- animals (Fig. III.1.9). YB-1 knock-down in Met-
RANTES-treated or Ccr5-/-/Apoe-/- mice did not lead to a significant change in the media 
and neointima size compared to empty vector-treated animals (Figure III.1.10), indicating 
that the YB-1 effect on atherosclerotic lesion formation is mediated through RANTES 
alone.  
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Fig III.1.9: YB-1 expression in the lesional area 
in Ccr5+/+ H1.shYB-1 treated animals was 
significantly reduced. Analysis of 5-6 sections of 
5 carotid arteries by immunofluorescence staining 
for YB-1 revealed that the expression was 2.5-fold 
higher in H1.empty-treated vessels compared to 
arteries with YB-1 knock-down (*P<0.05, when 
compared with H1.empty-transfected carotid 
arteries). 
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Fig. III.1.10: Vascular remodelling after wire injury was RANTES-mediated. Serial tissue sections of 
carotid arteries were stained with Movat’s pentachrome, and the medial (A) and neointimal (B) area was 
analyzed. Treatment of Apoe-/- (Ccr5+/+) carotid arteries with H1.shYB-1 showed a significant decrease in 
both the medial and neointimal area (*P<0.05, when compared with H1.empty-transfected carotid arteries; 
**P<0.01, when compared with H1.empty-transfected carotid arteries). Ccr5-/- and Met-RANTES-treated 
animals displaced a similarly reduced neointimal area as the Ccr5+/+ mice, which were treated with YB-1 
shRNA (B), but the plaque area was not further reduced, when those carotid arteries were treated with 
H1.shYB-1. 
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The infiltration of macrophages in the lesion is a major event in atherosclerosis 
progression. Therefore, the macrophage content in carotid arteries with and without 
lentiviral knock-down was compared in Apoe-/- mice. As shown in Fig. III.1.11, the 
inhibition of vascular remodelling in H1.shYB-1-treated Apoe-/- mice was associated with a 
significant decrease in the medial and neointimal content of Mac-2+ macrophages in 
H1.shYB-1- compared to H1.empty-transfected carotid arteries. 
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Fig. III.1.11: The macrophage content in 
lesions with YB-1 knock-down was 
significantly reduced. Serial tissue sections were 
stained for the macrophage marker Mac-2. 
Macrophage infiltration in the lesional area 
(media and neointima) of H1.shYB-1-treated 
carotid arteries 4 weeks after wire injury were 
compared with H1.empty-transfected carotid 
arteries; (*P<0.05 and **P<0.01, when compared 
with H1.empty-transfected carotid arteries). 
 
III.1.6 Interference with chemokine functions or regulation 
mechanisms 
The above-presented study intented to find out, if and how YB-1 is involved in 
RANTES expression regulation and how this regulation affects RANTES-mediated 
atherosclerosis. Unsterstanding the expression regulation of a chemokine is one 
important step towards finding a suitable therapeutic target. Nevertheless, a direkt 
blockade of the chemokine receptor activation or the interaction of a chemokine or CLF 
chemokine with other molecules by small molecule antagonists may also be a promising 
approach to the treatment or various diseases. The following study intented to identify a 
receptor for the CLF chemokine MIF and novel chemokine functions of the CLF 
chemokine MIF, as well as new insights in MIF’s impact on atherogenesis. 
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III.2 The CLF chemokine MIF and atherosclerotic lesion 
formation 
III.2.1 MIF triggers monocyte arrest in flow through CXCR2 
Due to the findings that the MIF monomer bears a structural resemblance to the IL-8 dimer 
(Fig. I.4) (Sun et al. 1996) and given the fact that Gro-α, IL-8 and their receptor CXCR2 
have been identified as major ligand-receptor pairs promoting monocyte arrest (Gerszten et 
al. 1999; Weber et al. 1999), a flow adhesion assay, using blocking mAbs and pertussis 
toxin (PTX), was employed to explore whether MIF-induced monocyte arrest was 
dependent on Gαi protein-coupled activities of CXCR2. Confluent HAoEC were pretreated 
with MIF for 2 h to immobilize it on the monolayer surface (Fig. III.2.1). Then, calcein-
stained monocytes or cells of the MonoMac6 cell line were perfused over the cell 
monolayer at 1.5 dyn/cm², resembling physiological shear flow. MIF presentation 
provoked a substantial increase in the arrest of primary monocytes and MonoMac6 cells 
after 2 min of perfusion, an effect specifically blocked by a MIF mAb (Fig. III.2.2). The 
MIF-triggered but not spontaneous monocyte arrest was ablated by the CXCR2 mAb or 
PTX, consistent with the established role of Gαi activity in chemokine receptor signaling. 
Furthermore, mAbs against the classical CXCR2 agonist chemokines Gro-α and IL-8 did 
not interfere with the arrest-promoting function of MIF (Fig. III.2.2, A).  
 
100 µm
100 µm
MIFcontrol
HAoEC
CHO/
ICAM-1
 
Fig. III.2.1: MIF was immobilized on the cell 
surface of HAoEC and CHO/ICAM-1 cells. 
Immunofluorescence using a rabbit MIF 
antiserum, followed by the respective FITC-
conjugated mAb, revealed surface presentation of 
MIF (green; blue: cell nuclei) on HAoEC and 
CHO/ICAM-1 cells after pretreatment for 2 h. In 
contrast, MIF was absent in buffer-treated cells 
(control).  
 
To further exclude the presence of CXC chemokines (e.g. with an ELR-motif) 
specialized in triggering integrin-dependent arrest, CHO cells expressing the β2 integrin 
ligand ICAM-1 were also employed as a model system to dissect the mechanisms utilized 
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by MIF to promote monocytic cell arrest (Fig. III.2.3). Under flow conditions, ICAM-1 
expression supported the constitutive arrest of MonoMac6 cells. Exposure of the CHO 
transfectants to MIF for 2 h led to its immobilization on the cell surface (Fig. III.2.2) and, 
similar to exposure with IL-8, increased monocytic cell arrest (Fig. III.2.3, A). MIF-
induced adhesion was fully sensitive to PTX and inhibited by a blocking β2 mAb (Fig. 
III.2.3, A), confirming the role of Gαi signaling in β2 integrin-mediated arrest induced by 
MIF. Both primary monocytes and MonoMac6 cells express the IL-8 receptors CXCR1 
and CXCR2 (Weber et al. 1999). While a blocking CXCR1 mAb had no significant effect 
and blocking CXCR2 substantially but not fully attenuated the arrest functions of MIF, 
combining these mAbs completely inhibited monocytic cell arrest triggered by MIF. In 
addition to CXCR2, the MIF-binding membrane protein CD74 was involved in MIF-
induced monocyte arrest, as shown by mAb inhibition (Fig.2.3, B). None of the mAbs 
significantly inhibited spontaneous arrest (data not shown). This clearly indicates that 
CXCR2 mediates the arrest function of MIF. Moreover, fully efficient arrest appeared to 
involve adjuvant functions of CD74 and, to a minor extent, CXCR1. 
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Fig. III.2.2: MIF-triggered arrest of monocytes and monocytic MonoMac6 cells on endothelial cells 
was mediated by CXCR2. Human aortic endothelial cells were perfused with human primary monocytes 
(A) and cells of the human monocytic MonoMac6 cell line (B). Adherent HAoEC monolayers were 
preincubated with or without recombinant MIF (50 ng/mL) for 2 h and perfused with monocytic cells at a 
flow rate of 1.5 dyn/cm² for 2 min. MIF-mediated arrest of primary monocytes or MonoMac6 cells was 
inhibited by pretreatment with mAbs to MIF or CXCR2, or with pertussis toxin (PTX) as indicated. 
Monocyte arrest is expressed as cells/mm². The blocking mAbs against Gro-α and IL-8 did not have an 
effect on MIF-triggered monocyte arrest (A). 
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Fig. III.2.3.: β2 integrin-mediated arrest induced by MIF was abolished by PTX and αCXCR2 and 
αCD74 mAbs. MIF-treated CHO/ICAM-1 monolayers were perfused with MonoMac6 cells at 1.5 dyn/cm2 
for 2 min. Binding to vector-transfected CHO cells was subtracted. (A) MIF provoked a similar adherence of 
the cells as IL-8 and cell arrest was significantly blocked by PTX or the antibody TS1/18, which specifically 
binds the β2-subunit of αLβ2. (B) MIF-mediated MonoMac6 arrest was monitored after pre-treatment with 
blocking mAbs against CXCR1 and/or CXCR2 or CD74.  
 
III.2.2 MIF triggers T cell arrest in flow through CXCR4 
The next aim was to evaluate whether the potential ligand function of MIF extends to other 
CXCRs. Isolated and activated T cells do not express CXCR2 or the expression is very low 
(Cockwell et al. 2002; Takata et al. 2004), but MIF has been shown to activate T cells and 
to induce signaling processes through Src-family kinases (Calandra and Roger 2003; Lue 
et al. 2006). Since the CXCR4 ligand SDF-1α has been implicated in integrin-dependent 
arrest of T cells via the Src-family kinase p56lck (Feigelson et al. 2001; Weber et al. 2001), 
flow adhesion assays were performed to explore if MIF can act through CXCR4. MIF or 
SDF-1α immobilized on HAoEC triggered the arrest of primary human IL-2-stimulated 
effector T cells. MIF-induced but not spontaneous T cell arrest was inhibited by a mAb 
against CXCR4 and was sensitive to PTX (Fig. III.2.4, A). Presentation of MIF or SDF-1α 
on CHO/ICAM-1 transfectants supported the αLβ2-dependent arrest of Jurkat T cells, an 
effect specifically inhibited by blocking CXCR4 (Fig. III.2.4, B).  
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Fig. III.2.4: MIF triggered T cell adhesion on CHO/ICAM-1 monolayers through CXCR4. MIF-treated 
CHO/ICAM-1 monolayers were perfused with primary human T cells and Jurkat T cells at 1.5 dyn/cm2 for 2 
min. Then firmly adherent cells were counted. Binding to vector-transfected CHO cells was subtracted. 
 
 
Since MonoMac6 cells and primary monocytes showed a strong CXCR2-dependent 
response to MIF stimulation, Jurkat T cells that do not express endogenous CXCR2 
(Fig.III.2.5, A), were transiently transfected with pcDNA3.1/CXCR2, and flow 
experiments were performed with these cells 48 h after transfection. CXCR2 expression 
was confirmed via FACS analysis prior to the experiments (Fig. III.2.5, B).  As revealed by 
the arrest data (Fig. III.2.6), ectopic expression of CXCR2 in Jurkat T cells further 
increased MIF-triggered arrest corroborating that CXCR2 imparts enhanced 
responsiveness to MIF in leukocytes. 
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A                                                B                                             C 
 
Fig. III.2.5: FACS analysis of Jurkat cells. (A) Jurkat cells were stained for CXCR2 and CXCR4, or treated 
with isotype control. (B) Jurkat cells were transfected with control vector (Jurkat/pcDNA3.1) or CXCR2 
expression vector (Jurkat/pcDNA.3.1/CXCR2) via the Amaxa Nucleofector device. After 24 h, CXCR2 
expression was confirmed by an αCXCR2/FITC mAb. (C) Transfection efficiency was determined by 
transfection of the Jurkat cells with a provided vector coding for the green fluorescent protein (pmaxGFP); 
Transfection efficiencies were ~70%. 
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Fig. III.2.6: CXCR2 expression led to an 
increased T cell arrest in response to MIF. Jurkat 
T cells were transfected with the CXCR2 
overexpression vector pcDNA3/CXCR2. 48 h 
afterwards, the cells were perfused over 
CHO/ICAM-1 cell monolayers. Cell arrest is given 
in % of empty vector transfectant cells. 
 
Further experiments to elucidate the role of CXCR2 receptor in MIF action were 
performed using murine L1.2 pre-B lymphoma cells transfected to express either CXCR1, 
CXCR2, or CXCR3, and controls expressing endogenous Cxcr4 only. These experiments 
were carried out in the presence or absence of the CXCR4 antagonist AMD3645. 
Expression of CXCR1, CXCR2 and CXCR3 was verified prior to the flow adhesion 
experiments (data not shown). While MIF triggered the arrest of the CXCR2 transfectants 
and Cxcr4 expressing cells with similar efficacy as the bona fide ligands IL-8 and SDF-1α, 
the CXCR1 and CXCR3 transfectants were only responsive to IL-8 and IP-10, 
respectively, but did not respond to MIF (Fig. III.2.7). These results establish that CXCR2 
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and CXCR4 but not CXCR1 or CXCR3 support MIF-induced arrest functions. 
Besides the arrest function, the chemotactic activity is a crucial feature of 
chemokines causing blood cells to transmigrate through the vessel wall to sides of 
inflammation. In parallel to the flow adhesion experiments, transmigration assays were 
performed by the members of the Institute of Biochemistry under supervision of Jürgen 
Bernhagen. According to the results of the cell arrest in shear flow, MIF displayed 
chemokine-like functions by stimulating monocyte, T cell and neutrophil chemotaxis 
through CXCR2 and CXCR4  (Bernhagen et al. 2007). 
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Fig. III.2.7: MIF induced cell arrest through CXCR2 and CXCR4, but not through CXCR1 or 
CXCR3. SVECs were perfused with L1.2 transfectants stably expressing CXCR1, CXCR2 or CXCR3, and 
with controls expressing only endogenous CXCR4, in the presence of the CXCR4 antagonist AMD3465. 
Arrest is quantified as cells/mm² (A) or as percentage of control cell adhesion (B). Data are results from one 
representative experiment (n = 3 measurements) of four experiments. 
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III.2.3 MIF triggers rapid activation of leukocytes 
To investigate if MIF induces other typical arrest chemokines engaging CXCR2, HUVEC 
and HAoEC were incubated with MIF (50 ng/mL) for 2 h. The expression of the CXCR2 
ligands IL-8 and Gro-α was determined via real-time-PCR (Fig. III.2.8) IL-8 protein 
concentration in cell supernatants were detected with an ELISA (Fig III.2.8). TNF-α-
treated cells served as positive controls. In contrast to TNF-α, pre-incubation of HAoEC 
and HUVEC with MIF for 2 h did not show an increase in IL-8 or Gro-α mRNA 
expression. Also, the IL-8 concentration in cell supernatants of both cell types was not 
increased after MIF incubation. 
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Fig. III.2.8. 2 h incubation with MIF did not lead to expression of typical CXCR2 ligands. HUVEC (A) 
or HAoEC (B) were stimulated with MIF or TNF-α or left untreated for 2 h, the expression of transcripts for 
the arrest chemokines IL-8 or Gro-α was analyzed by real-time PCR and normalized to control cells (left 
panel), and IL-8 protein was determined in the supernatants by ELISA (right panel). Three independent 
experiments were performed in duplicate. (B) Left panel shows one representative experiment of three 
independent experiments. 
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A direct short-term exposure to chemokines in solution or coated in juxtaposition to 
integrin ligands, e.g. vascular cell adhesion molecule (VCAM)-1 has been shown to 
stimulate rapid and transient up-regulation of integrin activity to mediate leukocyte arrest 
(Grabovsky et al. 2000; Chan et al. 2001). Integrin activation by immobilized or 
endothelial-bound chemokines is accomplished by induction of clustering (e.g. for α4β1) 
or of an extended conformation (e.g. for αLβ2) immediately preceding ligand binding. 
Accordingly, stimulation of monocytic cells with MIF in solution for 1-5 min triggered 
αLβ2-dependent arrest on CHO/ICAM-1 cells similar to IL-8 (Fig. III.2.9). 
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Fig. III.2.9: Direct stimulation of MonoMac6 
cells with MIF triggered αLβ2-dependent arrest. 
MonoMac6 cells were stimulated with MIF (250 
ng/mL) directly in solution and immediately 
perfused over CHO/ICAM-1 monolayers. Adhering 
cells were counted after 2 min.  IL-8 (100 ng/mL) 
served as positive control. 
 
Evidence for a direct stimulation of monocyte integrins was obtained by assays using 
the reporter mAb 327C, which recognizes an activation epitope corresponding to the 
extended high affinity conformation of αLβ2. MonoMac6 cells and primary monocytes 
were stimulated with MIF and fixed with PFA at certain time points. The activation of the 
αLβ2 integrin was analyzed via flow cytometry. This revealed that MIF-induced αLβ2 
activation occurred as early as 1 min after exposure and persisted for 30 min in MonoMac6 
cells (Fig. III.2.10, A). In isolated human blood monocytes, the activation of αLβ2 by MIF 
peaked at 2 min and also persisted for 30 min (Fig. III.2.10, B). To evaluate whether 
stimulation by MIF was restricted to αLβ2, monocytic cell arrest in flow on a VCAM-1 
substrate was examined. VCAM-1 supports firm adhesion in conjunction with active α4β1. 
Exposure to MIF for 1-5 min triggered substantial arrest, which was mediated by 
CXCR2/CD74 and α4β1, as shown by mAb inhibition (Fig. III.2.11, A). In contrast, 
blocking CXCR2 did not affect arrest of resting cells. As for SDF-1α, stimulation of Jurkat 
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T cells with MIF for 1-5 min triggered CXCR4-dependent adhesion on VCAM-1 (Fig. 
III.2.11, B). 
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Fig. III.2.10: MIF triggered rapid activation of αLβ2 on primary monocytes and MonoMac6 cells. (A) 
Cells of the MonoMac6 cell line were stimulated with MIF for the indicated times. αLβ2 activation was 
detected by the 327C antibody and monitored by FACSAria. The activation is expressed as the increase in 
mean fluorescence intensity (MFI). (B) The same experiment was performed with primary monocytes 
isolated from PBMC. Here, data are expressed relative to maximal activation with Mg2+ and EGTA. 
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Fig. III.2.11: MIF-triggered cell arrest on VCAM-1 substrate was dependent on CD74, CXCR2, and 
CXCR4. (A) MonoMac6 cells were pretreated with mAbs to α4β1 (αVLA-4) , CXCR2, CD74, and 
stimulated with MIF for 1 min and perfused on immobilized VCAM-1.Fc at 1.5 dyne/cm2 for 5 min. (B) 
MIF-triggered Jurkat T cell arrest on VCAM-1 substrate was tested with or without a mAb to CXCR4 or 
isotype control. 
 
Since CXCR2 is known to mediate increases in cytosolic calcium in response to IL-8 
in leukocytes or transfectants (Jones et al. 1997), the next aim was to study the ability of 
MIF to induce calcium influx. To do so, neutrophils were stained with the fluorescent dye 
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Fluo-4 AM, which exhibits an increase in MFI when it binds Ca2+. After addition of MIF 
(50 ng/mL), the cells were immediately analyzed in the FACSAria. MIF induced rapid 
calcium influx in primary human neutrophils and desensitized calcium transients in 
response to IL-8 and MIF, while IL-8 fully desensitized calcium signals both in response to 
IL-8 and MIF (Fig. III.2.12), indicating that MIF rapidly activates a GPCR/Gαi signaling 
pathway. The partial desensitization of IL-8 signals observed with MIF in neutrophils 
parallels findings with other CXCR2 ligands and likely reflects the presence of CXCR1, as 
MIF fully desensitized calcium influx in neutrophils that was induced by the sole CXCR2 
ligand Nap-2 (Fig. III.2.12). 
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Fig. III.2.12: MIF induced rapid calcium mobilization in neutrophils. Neutrophils were stimulated with 
MIF, IL-8 or NAP-2 as indicated and calcium-derived mean fluorescence intensity was recorded by flow 
cytometry (FACSAria) for 0-240 sec. For homologous and heterologous desensitization, IL-8, NAP-2 or MIF 
was added 120 sec before successive stimulation with IL-8 or MIF and vice versa. The traces shown are 
representatives of 4 independent experiments. 
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Fig. III.2.13: Dose-response curves of calcium influx triggered by IL-8, NAP-2 and MIF in 
L1.2/CXCR2 transfectants. L1.2 cells stably expressing CXCR2 were treated with the denoted 
concentrations and the change in MFI due to calcium influx was measured and recorded with the 
FACSAria. Data are expressed as the difference between baseline and peak MFI. 
 
To compare MIF potency in calcium mobilization with other CXCR2 ligands, 
L1.2/CXCR2 transfectants were employed (Fig. III.2.13). In those transfectants, MIF dose-
dependently induced calcium influx with the greatest cell response at a concentration of 
250 ng/mL. MIF was less potent and effective than IL-8 and NAP-2, which both caused 
the highest calcium influx at 100 ng/mL.  
 
III.2.4 MIF directly binds to the chemokine receptor CXCR2  
To corroborate its interaction with CXCR2, the binding of fluorescein-labeled MIF (250 
ng/mL) to HEK/CXCR2 cells compared to vector-transfected HEK cells was analyzed via 
flow cytometry (Fig. III.2.14, A). HEK/CXCR2 transfectants, but not vector controls, 
supported direct binding of labeled MIF.  To support the results of the FACS analysis, 
coimmunoprecipitations with vector controls and CXCR2-transfectants were performed. 
The cells were incubated with biotinylated MIF (250 ng/mL), lyzed and biotin-MIF/protein 
complexes were captured with streptavidin-coated beads. Western blot analysis proved the 
binding of MIF to CXCR2 (Fig. III.2.14, B). 
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Fig. III.2.14: MIF bound to the 
chemokine receptor CXCR2. HEK 
and HEK/CXCR2 cells were incubated 
with biotin- or fluorescein-labeled MIF 
for 30 min on ice. (A) Binding of 
fluorescein-MIF to HEK/CXCR2 
transfectants or vector controls (HEK) 
was analyzed by FACS. (B) 
Coimmunoprecipitation was performed 
with HEK and HEK/CXCR2 cells 
incubated with biotinylated MIF. 
Binding of biotin-MIF to CXCR2 was 
assessed by Western blot using the 
αCXCR2 RII115 after streptavidin 
pull-down from HEK/CXCR2 
transfectants versus vector controls. 
 
 
 
III.2.5 CXCR2 forms a complex with CD74 
CD74 is a receptor for MIF as discovered earlier (Leng et al. 2003). The results above 
demonstrate that MIF triggers leukocyte arrest through CD74 and CXCR2 (and to a lesser 
extend through CXCR4), leading to the assumption that there is a receptor complex 
involved in MIF action. To clarify if CXCR2 and CD74 form complexes on the cell 
surface, coimmunoprecipitations with cells of the murine B-lymphoma cell line L1.2 stably 
expressing CXCR2 and transiently transfected with pcDNA/his-CD74 were performed. 
After pull-down of CXCR2, complexes with CD74 were detected via Western blot (Fig. 
III.2.15). In contrast, no complexes were observed in protein precipitates with L1.2 
controls or the isotype control. 
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Fig. III.2.15: 
Coimmunoprecipitation of a 
CXCR2/CD74 complex. 
Coimmunoprecipitation was 
performed with precleared lysates 
of L1.2 cells stably expressing 
CXCR2 (right) and untransfected 
cells (left). Pull-down was done 
with a CXCR2-specific mAb or 
respective isotype control (IgG). 
CXCR2 (upper right) and CD74 
(lower right) were detected in the 
protein precipitates of 
L1.2/CXCR2 cells as assessed by 
western blotting. No CXCR2 or 
CD74 was detected in L1.2 
protein precipitates. 
 
III.2.6 CXCR2 mediates MIF-induced monocyte arrest on 
atherosclerotic endothelium 
The importance of MIF in the development of atherosclerosis and neointimal hyperplasia 
has been established by mAb blockade and genetic deletion. Furthermore, the murine 
CXCR2 ligand KC (IL-8 homologue) is crucial in eliciting α4β1-dependent monocyte 
accumulation in ex vivo-perfused carotid arteries of Apoe-/- mice with early atherosclerotic 
endothelium (Huo et al. 2001). To elucidate wether MIF/CXCR2 interactions are involved 
in monocyte accumulation in inflamed arteries, the induction of atherogenic recruitment by 
MIF and CXCR2 was tested in this ex vivo perfusion system. Carotid arteries of Apoe-/-, 
Mif+/+ and Mif-/- mice fed an atherogenic diet for 6 weeks were perfused ex vivo with 
fluorescence-labeled human MonoMac6 cells. Adhesive interactions with the 
atherosclerotic vessel wall were recorded using fluorescence illumination. 
Monocyte arrest in carotid arteries of Apoe-/- mice fed a high-fat diet for 6 weeks was 
inhibited by a blocking mAb to Cxcr2, and by mAbs to CD74 and MIF (Fig. III.2.16), 
indicating that besides KC, MIF contributed to atherogenic recruitment via Cxcr2, and via 
CD74. A similar pattern for the blockade of MIF, Cxcr2 or CD74 was observed for 
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monocyte arrest in carotid arteries of wild-type mice treated with TNF-α for 4 h as a model 
of acute vascular inflammation (Fig. III.2.16, B). Inhibitory effects of CD74 mAb were 
attenuated and blocking MIF was ineffective in arteries of TNF-α-treated Mif-/- mice, while 
a remaining inhibition of Cxcr2 suggested an involvement of other TNF-α-inducible 
ligands (Fig. III.2.16, C). 
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Fig. III.2.16: MIF-driven monocyte arrest in inflamed or atherosclerotic arteries involved CXCR2 and 
CD74. (A) Carotid arteries of Apoe-/- mice fed a western diet for 6 weeks were pre-perfused with a αMIF 
antibody solution or isotype control. Then the arteries were perfused with MonoMac6 cell treated with mAbs 
to CD74, CXCR2, isotype control (B, C) The same experiment with carotid arteries from wild-type (Mif+/+) 
and Mif-/- mice 4 h after intraperitoneal injection of TNF-α; At 10 min MonoMac6 cells not moving for 30 sec 
were defined as firmly adherent. Cells were counted in 5–6 fields per carotid artery. 
 
 
Compared to the effect of Mif deficiency observed with TNF-α stimulation, 
monocyte accumulation was more clearly impaired by Mif deficiency in arteries of  
Mif-/-/Ldlr-/- mice versus atherogenic Ldlr-/- mice (Fig. III.2.17). A contribution of Cxcr2 
was not apparent in the absence of Mif, and blocking Mif had no effect (Fig. III.2.17). In 
turn, both effects were restored by loading with exogenous MIF (Fig. III.2.17, C). 
Employment of the αCD74 mAb in Mif-/-/Ldlr-/- carotid arteries led to a stronger inhibition 
of MonoMac6 arrest than αCXCR2 or αMIF mAbs, but all mAbs had a similar potency in 
reducing adhesion in MIF-treated carotid arteries (Compare Fig. III.2.17, B and C). 
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Fig. III.2.17: MIF-driven monocyte arrest in inflamed or atherosclerotic arteries involved CXCR2 and 
CD74. MonoMac6 cell arrest in carotid arteries from Mif+/+/Ldlr-/- (designated Ldlr-/-) and Mif-/-/Ldlr-/- mice 
fed a western diet for 6 weeks; (C) Carotid arteries of Mif-/-/Ldlr-/- mice were loaded with MIF for 2 h before 
perfusion with MonoMac6 cells. After 10 min, adherent cells in 5–6 fields per carotid artery were counted. 
 
To further examine the relevance of CXCR2 for MIF-mediated monocyte 
recruitment in vivo, intravital microscopy on carotid arteries of chimeric wild-type and  
Mif-/- mice reconstituted with wild-type or Cxcr2-/- bone marrow was performed (Fig. 
III.2.18). 4 h following the i.p. injection of 1µg TNF-α, the accumulation of rhodamine-
labeled leukocytes was evaluated. Mif-/- mice with wild-type bone marrow displayed an 
attenuated cell arrest, as compared to wild-type mice. The deficiency in bone marrow 
Cxcr2 was associated with a more marked reduction in leukocyte accumulation in chimeric 
wild-type mice than in Mif-/- mice. 
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Fig. III.2.18: MIF-mediated leukocyte adhesion in vivo was dependent on CXCR2. For intravital 
microscopy, Mif+/+ and Mif-/- mice reconstituted with wild-type (WT) or Cxcr2-/- bone marrow were 
stimulated by intraperitoneal injection of TNF-α for 4 h, and the accumulation of leukocytes labeled by 
intravenous injection of rhodamine G was studied after 30 min in carotid arteries in vivo via epifluorescence 
microscopy. (A) Quantification of leukocyte arrest; representative images in B. 
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III.2.7 MIF-induced inflammation in vivo relies on CXCR2 
To further probe the effects of MIF in vivo, a model of MIF-induced peritonitis in chimeric 
mice reconstituted with wild-type or CXCR2-/- bone marrow was employed. 4 h after i.p. 
injection of 200 ng MIF, the peritoneal exudate was harvested by an i.p. lavage with sterile 
PBS. The number of immigrated neutrophils was analyzed by quantifying the number of 
Gr-1+CD115-F4/80- cells by flow cytometry.  
MIF elicited recruitment of neutrophils after 4 h in mice with wild-type bone 
marrow, demonstrating neutrophil responsiveness for MIF in vivo (Fig. III.2.19). 
Conversary, the deficiency in bone marrow CXCR2 abrogated MIF-stimulated peritoneal 
recruitment of neutrophils (Fig. III.2.19). 
 
N
eu
tr
o
ph
ils
(%
) 10
5
0
control controlMIF MIF
WT Cxcr2-/-
p < 0.05 p < 0.05
N
eu
tr
o
ph
ils
(%
)
N
eu
tr
o
ph
ils
(%
)
 
Fig. III.2.19: MIF and CXCR2 mediated 
inflammatory neutrophil recruitment in vivo.  
4 h after intraperitoneal MIF injection in mice 
repopulated with wild-type (WT) or Cxcr2-/- bone 
marrow, the content of neutrophils in the abdominal 
cavity was evaluated by flow cytometry. MIF 
elicited neutrophil recruitment in mice repopulated 
with WT, but not Cxcr2-/- bone marrow. 
 
III.2.8 MIF inhibition results in plaque regression  
Since MIF can act through both CXCR2 and CXCR4 and given the documented role of 
MIF and CXCR2 in the development of atherosclerotic lesions, the next approach was to 
test whether targeting MIF could modify advanced lesions and their content of both 
CXCR2-expressing monocytes and CXCR4-expressing T cells. Apoe-/- mice, which had 
received a high-fat diet for 12 weeks and had developed substantial and advanced 
atherosclerotic lesions, were treated with neutralizing mAbs to MIF, to KC or to SDF-1α 
for 4 weeks. In the aortic root, blocking MIF but not KC or SDF-1α resulted in a marked 
reduction of plaque area compared to untreated mice at 16 weeks and a significant 
regression of plaque size compared to baseline at 12 weeks (Fig. III.2.20). Blocking MIF 
but not KC or SDF-1α was associated with a decreased content of both macrophages and 
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CD3+ T cells at 16 weeks, indicating a more stable plaque phenotype (Fig. III.2.21).  
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Fig. III.2.20: Blocking MIF led to a declined plaque area. Apoe-/- mice received a high-fat diet for 12 
weeks and were subsequently treated with antibodies to Mif, KC or SDF-1α, or with vehicle (control) for an 
additional 4 weeks. Plaques in the aortic root were stained using Oil-Red-O. Blocking Mif but not KC or 
SDF-1α resulted in regression and stabilization of advanced atherosclerotic plaques. Representative images 
show the plaque area at baseline (12 weeks) and after 16 weeks. (B) Plaque area was quantified and given as 
% of the total aortic root surface. 
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Fig. III.2.21: Targeting MIF led to a more stable plaque composition. Aortic root sections Apoe-/- mice 
(Fig. III.2.19) were stained with mAbs specific for the macrophage marker (MOMA2) and for the T-cell 
marker CD3. As revealed by quantifying the fluorescent cells, treatment with αMIF mAb lead to a significant 
decrease in macrophage and T-cell content. 
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IV Discussion 
IV.1 Expression regulation of a chemokine involved in 
atherosclerosis 
IV.1.1 YB-1 regulates RANTES expression  
It has been previously reported that YB-1 affects the expression of various proliferative 
and inflammatory proteins, such as GM-CSF and MMP-2 at both the transcriptional and 
translational level (Mertens et al. 1997; Capowski et al. 2001). Depending on the cell-type, 
MMP-2 expression is up- or down-regulated by YB-1. Whereas YB-1 trans-activates the 
MMP-2 promoter in glomerular mesangial cells, the authors observed a YB-1-mediated 
repression of MMP-2 in the epithelial cells. Likewise, a cell-type-dependent repression of 
the RANTES gene by the proto-oncogene c-MYC has been described (Cappellen et al. 
2007).  
This work provides evidence that YB-1 upregulates RANTES expression in vascular 
SMC by the use of luciferase reporter assays, real time-PCR and ELISA. The knock-down 
of YB-1 by a shRNA resulted in diminished RANTES promoter activity, as well as in an 
inhibited secretion of RANTES by vascular SMC. The luciferase reporter experiments with 
the truncated promoter construct revealed that the region upstream of the -168 position was 
necessary for YB-1-mediated transcription activation. This finding is in concert with the 
EMSA results, which confirmed that YB-1 bound to the -204/-173 region of the RANTES 
promoter. Conversely, YB-1 seems to act as a trans-repressor for RANTES expression in 
macrophages, as YB-1 over-expression in RAW264.7 cells inhibited IFN-γ-induced 
activation of the RANTES promoter. Recently, Samuel at al. (2007) described an 
inhibitory effect of YB-1 on the MMP-13 expression by binding to AP-1 sites, suggesting 
that YB-1 is a new repressor in AP-1 target genes. It has also been shown that AP-1 and 
the NF-κB response elements participate in the LPS mediated activation of RANTES 
expression in macrophages (Hiura et al. 1999). Thus, YB-1 may repress RANTES gene 
activation in macrophages by binding to the AP-1 response element. Furthermore, 
repression might be due to preferential binding of YB-1 to single-stranded DNA, which 
can prevent other transcription factors from binding to enhancer regions in a cell-type 
specific manner, as has been described for the MHC class II genes (MacDonald et al. 
1995).  
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YB-1 has been shown to synergistically interact with other transcription factors, 
including AP-2 and p65, a subunit of NF-κB (Raj et al. 1996; Mertens et al. 1998), and 
synergistic activators of the RANTES promoter have been described, including NF-κB, 
IRF-3 and IRF-7 (Genin et al. 2000). Besides the activation of RANTES in SMC by direct 
promoter binding, it is conceivable that YB-1 might also trans-activate other transcription 
factors that are involved in the regulation of RANTES, e.g. NF-κB and C/EBP (Miyamoto 
et al. 2000; Fessele et al. 2001). 
 
IV.1.2 YB-1-regulated RANTES contributes to neointimal lesion 
formation 
The capability of Met-RANTES to diminish diet-induced neointima formation after arterial 
injury in Apoe-/- mice and the protective effects of the deficiency in the RANTES receptor 
Ccr5 during injury-induced neointimal hyperplasia but also native and diet-induced 
atherosclerosis (Schober et al. 2002; Braunersreuther et al. 2007) has validated the 
chemokine RANTES to be of paramount importance in vascular pathophysiology and 
lesion formation. Thus, understanding the regulation mechanisms of the RANTES gene 
may provide a platform for therapeutic strategies of vascular diseases. 
This study provides in vivo evidence that the expression of YB-1 is upregulated after 
injury and that it serves as a strong activator of RANTES expression in SMC. YB-1 knock-
down using shRNA led to a significant decrease in neointimal and medial hyperplasia after 
injury, but also reduced macrophage infiltration. Interestingly, these in vivo effects of  
YB-1 knock-down during the process of remodeling resemble findings obtained on the 
injury-induced neointima formation in Met-RANTES-treated mice or in mice deficient in 
its receptor Ccr5 (Schober et al. 2002; Veillard et al. 2004; Zernecke et al. 2006). 
However, due to the fact that several chemokines, such as MCP-1 or IL-8, are non-
redundantly involved in lesion formation (Weber et al. 2004), it is possible, that YB-1 
effects are not exclusively mediated through the regulation of RANTES. This might be in 
line with the findings that the YB-1-induced monocyte arrest on SMC was not completely 
blocked by Met-RANTES. Moreover, besides SMC, platelets, macrophages and other cell-
types not affected by YB-1 knock-down but involved in the pathogenesis of vascular 
remodeling may be an additional source of RANTES (Pattison et al. 1996; Schober et al. 
2002). 
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Previously, YB-1 expression was shown to be upregulated in infarcted areas of the 
heart (Kamalov et al. 2005) and during mesangioproliferative renal disease, the latter being 
induced by PDGF-B via a mitogen-activated protein kinase-dependent signaling pathway 
in mesangial cells (van Roeyen et al. 2005). Furthermore, α-smooth muscle actin 
expression in lung myofibroblasts is YB-1 dependently up-regulated after exposure to 
thrombin or TGF (Zhang et al. 2005), Thrombin has also been shown to induce a cleavage-
dependent activation of YB-1 protein and its nuclear translocation in endothelial cells, 
which can subsequently induce expression of the B chain isoform of platelet-derived 
growth factor (PDGF-B) (Stenina et al. 2000). Triggered by exposure of subendothelial 
matrix after endothelial-denudation injury, thrombotic events and thrombin formation 
might also contribute to the activation of YB-1 in this model. Since PDGF-B is also 
expressed after arterial injury and its inhibition is known to reduce neointima formation 
(Sirois et al. 1997; Deguchi et al. 1999; Raines 2004), it is not inconceivable that an auto-
stimulatory loop of PDGF-B-mediated YB-1 activation may amplify the expression of 
PDGF-B, besides effects on RANTES expression, and may thus contribute to enhanced 
neointimal hyperplasia after injury. In addition, because several chemokines, such as  
MCP-1 and IL-8, are nonredundantly involved in lesion formation, and taking into account 
that the YB-1-induced monocyte arrest on SMCs was not completely blocked by Met-
RANTES, one can assume that YB-1 effects were not mediated exclusively through 
regulation of RANTES. However, YB-1 knockdown in Ccr5-/- or Met-RANTES-treated 
mice did not lead to the expected further decline in plaque area, indicating that the 
contribution of YB-1 to neointima formation appears to require RANTES as a 
transcriptionally regulated mediator. 
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IV.1.3 Perspectives 
This study demonstrates that YB-1 is a novel regulator of RANTES expression. An 
increased activity of YB-1 in inflammatory SMC and after arterial injury up-regulates the 
expression of RANTES and thereby controls the RANTES-mediated monocyte adhesion 
and contributes to neointimal lesion formation in atherosclerosis-prone Apoe-/- mice. 
Since YB-1 can activate and/or repress RANTES expression, as seen in the 
macrophage cell line RAW264.7, the effects of YB-1 on other cell types and cell functions 
involved in atherogenesis clearly need to be addressed. Moreover, the exact repressive and 
activating mechanisms of YB-1 and a possible interaction with other transcription factors, 
remain to be elucidated. For instance, the possibility that YB-1 binds to the AP-1 response 
module in the RANTES promoter requires further examination. For a start, the 
employment of luciferase reporter assays using truncated or mutated promoter sequences 
and binding assays using EMSA epitomize suitable approaches. 
The above-mentioned in vitro and in vivo experiments disclosed that YB-1 is a potent 
mediator of neointimal plaque growth via upregulation of RANTES expression. Thus  
YB-1 may be a suitable target in the treatment of vascular disease extending previous 
findings that suggest an interference with mechanisms regulating the expression of 
RANTES. Blockade of YB-1 expression might be achieved by a regional, i.e. vascular 
transfer of shRNA as studied in this work. But not only shRNA-mediated knock-down of 
YB-1, also the interference with YB-1 actions via antibodies, small molecule antagonists 
and inactivation by proteases may be applicable to prevent restenosis, after arterial 
angioplasty and stenting. This could be achieved by the use of drug-eluting stents. 
However, given the ubiquitous expression and pleiotropic functions of YB-1, systemic 
effects need to be taken into account and should be carefully scrutinized.  
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IV.2 Novel chemokine-like functions of MIF 
IV.2.1 MIF exhibits chemokine functions through CXCR2 and 
CXCR4 
This work identifies CXCR2 and CXCR4 as functional receptors for MIF. The in vitro 
adhesion assays revealed that MIF, immobilized on HAoEC and CHO/ICAM-1 
monolayers, triggers leukocyte arrest directly through CXCR2, CXCR4 and the previously 
identified MIF-receptor CD74 (Leng et al. 2003). Hereby, MIF exhibited a similar 
efficiacy as the CXC chemokines IL-8 and SDF-1α. Involvement of other CXCR ligands 
was excluded by blocking mAbs and expression analysis, respectively. It was shown that 
MIF directly triggers integrin activation, as direct stimulation of MonoMac6 and Jurkat T 
cells for 1-5 min also led to αLβ2- and α4β1-dependent arrest, and rapid αLβ2 activation 
was demonstrated on MonoMac6 cells and primary monocytes using an antibody 
recognizing the active conformation of αLβ2. Furthermore, it was demonstrated that MIF 
diretly provokes calcium mobilization obviously not requiring CD74 as neutrophils 
affected by MIF do not express this cell surface protein. MIF/CXCR2-mediated Ca2+ 
mobilization led to a complete desensitization of the NAP-2 calcium signal. However, MIF 
was less potent in triggering calcium response compared to IL-8 and NAP-2. In addition to 
these data, the group of Prof. Bernhagen (UK Aachen) demonstrated that MIF also triggers 
leukocyte chemotaxis through the receptors CXCR2 and CXCR4, respectively (Bernhagen 
et al. 2007). A direct interaction of MIF and CXCR2 has been demonstrated by 
coimmunoprecipitation and FACS analysis in this study. Moreover, although binding of 
MIF to CXCR4 has not been shown yet, receptor competition experiments with I125SDF-1α 
strongly favor a direct interaction of MIF and CXCR4 (Bernhagen et al. 2007). 
Similar to IL-8, which has a wide range of actions on various types of cells (Mukaida 
2003), this study proves that MIF affects monocytes and neutrophils through CXCR2. The 
latter was confirmed by MIF-induced peritoneal neutrophil recruitment assays with  
mice reconstituted Cxcr2-/- bone marrow. In addition, a recently published work 
demonatrated that MIF promotes mouse embryonic fibroblast migration (Dewor et al. 
2007). The arrest activity of MIF extends to T cells, as it has the ability to interact with 
CXCR4. 
The presented data proposes the addition of a new class of chemokines to the 
approved kategorization. According to the existing classification of chemokines (Murphy 
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et al. 2000), MIF could be referred to as a ∆C chemokine, taking into account that the MIF 
monomer lacks the typical N-terminal cysteines. Regarding the structural resemblance of 
the MIF monomer to the IL-8 dimer (Sun et al. 1996), and the pseudo-ELR motif formed 
by the amino acid residues R11 and D44 with appropriate spacing, MIF seems to mimic 
ELR+ chemokines. It has been shown that IL-8 forms bioactive (hetero-)dimers and that 
homodimers form upon binding to CXCR2 but not to CXCR1 (Schnitzel et al. 1994; 
Deforge et al. 2000; Nesmelova et al. 2005), which is in line with this work, showing that 
MIF acts through CXCR2, but apparently does not affect leukocytes through CXCR1. 
 On the other hand, MIF has been proposed as a CLF-chemokine, a group comprising 
chemotactic polypeptides, e.g. defensins that differ from chemokines in size and shape. 
Like the human β-defensins HBD1 and HBD2, which bind and activate CCR6 to induce 
chemotaxis of immature dendritic and memory T cells (Yang et al. 1999), MIF is 
upregulated in various tissues after exposure to microbial products (Calandra and Roger 
2003). Furthermore, MIF plays a role in sepsis similar to the proposed CLF-chemokine 
HMGB1 (high mobility group box) (Degryse and de Virgilio 2003). The three-dimensional 
resemblance of MIF and the IL-8 dimer are in accord with the postulation that some of 
these CLF-chemokines share tertiary structural features with the corresponding bona fide 
ligands that enable them to utilize chemokine receptors.  
Beyond the functional and structural resemblance with the CLF class members and 
the IL-8 dimer, MIF exhibits enzymatic activities, such as D-dopachrom-tautomerase and 
oxidoreductase activity, which is dependent on a Cys57-Ala-Leu-Cys60 (CALC) motif. 
The oxidoreductase activity of MIF has also been linked to its immunogenic properties,   
and enzymes with chemoattractive properties have been described before: An N-terminal 
fragment of tyrosyl-tRNA-synthetase binds to CXCR1 stimulating chemotaxis of 
neutrophils, and thioredoxin, a redox enzyme released by various cell types upon 
activation, is a chemo-attractant for leukocytes (Bertini et al. 1999; Wakasugi and 
Schimmel 1999). As the oldest known inflammatory cytokine, MIF may represent a 
prototypic member of the chemokine species combining CLF, chemokine and enzymatic 
features. 
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IV.2.2 Co-function of CD74 in a CXC receptor complex  
It was further demonstrated that MIF-induced activation of atherogenic or inflammatory 
arrest of monocytes is not only dependent on CXCR2. As a cell surface binding protein for 
MIF, CD74 also is involved and co-localizes with CXCR2, as shown by co-
immunoprecipitation. Thus, it is conceivable that MIF signals through a functional 
CXCR/CD74 complex, although the Ca2+ mobilization experiments with neutrophils 
proved that the involvement of CD74 is not crucial for cell activation. However, the 
association with CD74 may facilitate the activation of CXCR2, as it has been shown that 
binding of MIF to CD74 induced a signaling cascade involving the proteoglycan CD44 and 
Src-family kinases (Shi et al. 2006). In conjunction, CD74, CD44 and Src could represent a 
functional receptor tyrosine kinase (RTK)-like complex, and it has been reported that RTK 
complexes can trans-activate GPCRs and vice versa (Akekawatchai et al. 2005; Waters et 
al. 2005). Additional binding of MIF to CD74 may facilitate GPCR activation and 
formation of a signaling complex with Src kinases. A similar mechanism has been 
described for the chemokine RANTES. The authors observed a formation of a Src 
kinase/CD44 signaling complex upon RANTES binding to the glycosaminoglycans of 
CD44 (Roscic-Mrkic et al. 2003). In another study, it has been shown that sphingosine-1-
phosphate trans-activates CXCR4 via Src-family kinases in human progenitor cells (Walter 
et al. 2007). Fig. IV.1 shows the extended sketch of MIF-induced cell response according 
to the findings of this work combining CXCRs with the proposed RTK-like complex. As 
inferred by the profound effects of blocking CD74, this study further implies that CD74 
may also participate in Gro-α/IL-8-induced signaling via CXCR2 independently of MIF to 
accomplish atherogenic cell recruitment. This role of CD74 is further underscored by its 
preferential expression on mononuclear cell types relevant to atherosclerosis (Leng et al. 
2003).  
Recapulatory, these data extend other studies pointing toward a large GPCR/RTK(-
like) complex, which is able to react in a stimuli-rich environment. 
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Fig.IV.I: MIF’s mechanisms of action. MIF (blue trimer) binds to CXCR2 and possibly to CXCR4. MIF 
signaling occurs through a receptor complex formed by CD74, CD44 and at least one CXCR and elicits rapid 
cell responses as calcium mobilization and integrin activation. MIF signaling mechanisms through CXCR2 
and CXCR4 alone remain to be elucidated (modified from Morand et al. 2006 and Zernecke et al. 2008 (in 
press)). 
 
 
IV.2.3 Targeting MIF in vivo causes atherosclerosis regression 
This study provides ex vivo and in vivo evidence for MIF’s inflammatory actions 
employing perfusion of explanted carotid arteries, as well as intravital microscopy in 
carotid arteries with early atherosclerosis. Especially, a peritonitis model and linking 
CXCR2 and MIF deficiency in bone marrow chimeras demonstrated the direct functional 
involvement of CXCR2 in MIF-triggered monocyte recruitment in vivo. Previous studies 
investigated the contribution of MIF to atherogenesis (Pan et al. 2004; Schober et al. 
2004), but its potential to activate T cells have not been taken into account, just as only the 
MIF function in atherosclerosis initiation has been evaluated, but its role in plaque 
progression has not been determined. The role of CXCR2 regarding atherosclerosis 
progression has been well established (Boisvert et al. 2006). The authors found that the 
genetic deletion of KC/Gro-α in Ldlr-/- mice less markedly reduced atherosclerosis than 
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deletion of leukocyte CXCR2, but that both predominantly affected macrophage 
accumulation in progressed atherosclerosis. This led to the assumption that another ligand 
is, at least, partially involved in CXCR2-triggered lesion formation. Accordingly, the work 
at hand discloses the additional role of MIF as a T cell agonist, and its potential to induce 
plaque progression. This study shows for the first time that antibody blockade of MIF but 
not of the cognate CXCR2 and CXCR4 ligands KC/Gro-α or SDF-1α alone leads to a 
marked regression of advanced pre-existing atherosclerotic plaques in Apoe-/- mice on a 
high-fat diet, and that inflammatory cell content (both macrophages and T cells) was 
reduced, entailing a more stable plaque phenotype. The present data recognizes MIF as 
being the additional CXCR2 ligand actively involved in advanced atherosclerosis. As an 
additional feature, blocking MIF impairs CXCR4-supported T cell recruitment, which is 
also a critical force driving lesion formation.  
 
IV.2.4 Perspectives 
This work unveils that MIF is a non-cognate CXCR ligand. Furthermore, the intrinsic 
effects of MIF/CXCR2 interaction on inflammation and atherosclerosis progression have 
been investigated to a great extent. The next goal is to clarify the interaction of MIF with 
CXCR4, and if CXCR4 also forms a receptor complex with CD74 (and CD44/Src kinase 
signaling complex) and CXCR2. This could be done by coimmunoprecipitation 
experiments or, alternatively, by making use of the Fluorescence Resonance Energy 
Transfer (FRET) which occurs, if a CFP- and YFP-coupled protein, respectively, are in 
immediate vicinity. Besides, future studies should clearify, if GPCRs trans-activate 
CD74/CD44/Src complex or if the RTK-like complex acts upstream of the GPCRs. Since 
the activation of the CXCR2 receptor requires the presence of an ELR motif (Jones et al. 
1997), and because of the pseudo-ELR motif (Fig. I.4) which is formed by the amino acid 
residues on two adjacent β-helices, it is important to examine, if this pseudo-ELR motif is 
crucial for MIF/CXCR2/4 and CD74 interaction. This could be accomplished by binding 
assays and functional experiments with MIF mutants (with substituted amino acids at 
position 11 and/or 44). Furthermore, it would be interesting to discover the CXCR/MIF 
interface by exchanging the three extracellular loops and the N-terminus of the CXCR2 
receptor with the respective parts of a non-MIF-interacting GPCR, for example with the 
extracellular domains of CXCR3. 
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The number of chemokine receptor antagonists developed to target atherosclerosis 
and other inflammatory diseases, e.g. the above-mentioned CCR5 antagonist Met-
RANTES, is rapidly expanding and a substantial amount of evidence has been gathered in 
favor of this therapeutic strategy despite the apparent redundancy in the chemokine system 
(Proudfoot 2002). This study identifies MIF as a non-cognate CXCR agonist, thereby 
extending the approaches for therapeutic strategies that target MIF effects on 
atherosclerosis and other inflammatory diseases. Small peptide antagonists based on the 
MIF structure may be able to inhibit CXCR2 and/or CXCR4-mediated inflammatory 
events.  
Beyond current strategies promoting reverse cholesterol transport by apolipoprotein 
mimetics and raising HDL-cholesterol levels by interfering with the cholesterol 
metabolism or altering the cholesterol composition (Navab et al. 2004), targeting MIF may 
emerge as a suitable strategy to achieve therapeutic regression and stabilization of manifest 
and advanced atherosclerosis.  
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V Summary 
This study surveys the expression control and the down-stream effects of two mediators 
that have a severe impact on atherosclerosis progression.  
The first approach identified YB-1 as a new transcriptional regulator of the CC 
chemokine RANTES. RANTES is upregulated in mononuclear cells or deposited by 
activated platelets during inflammation and has been implicated in atherosclerosis and 
neointimal hyperplasia. Here, the influence of YB-1 on RANTES expression and its 
contribution to neointima formation after guide-wire injury has been investigated. The 
binding of YB-1 to position -214/-173 was confirmed by DNA binding studies. Increased 
expression of both YB-1 and RANTES mRNA in neointimal versus medial SMC 
suggested a regulatory function of YB-1 for RANTES expression and, indeed, 
overexpression of YB-1 in smooth muscle cells (but not macrophages) enhanced RANTES 
transcriptional activity in reporter assays, mRNA and protein expression, and RANTES-
dependent monocyte arrest in shear flow. Furthermore, intraluminal transfection of carotid 
arteries of hyperlipidemic Apoe-/- mice with a lentivirus encoding YB-1 shRNA directly 
after wire injury led to a significant reduction in plaque area and macrophage content. YB-
1 was expressed in neointimal SMC but not macrophages and colocalized with neointimal 
RANTES, which was downregulated by YB-1 shRNA. A further reduction of lesion 
formation by YB-1 knockdown was not observed in Apoe-/- mice deficient in the RANTES 
receptor Ccr5 or after treatment with the RANTES receptor antagonist Met-RANTES, 
which indicates that YB-1 effects were dependent on RANTES. Thus, local blockade of 
YB-1 might become a suitable strategy in preventing restenosis after balloon angioplasty. 
 
The second part of this work intended to elucidate the mechanisms of the pleiotropic 
functions of the CLF chemokine MIF. MIF plays a critical role in inflammatory diseases 
and atherogenesis and attracts immune cells to sites of inflammation. The only known cell 
surface receptor for MIF is CD74, which can mediate sustained activation of ERK/MAPK. 
Yet, no receptor had been discovered that would be able to confer MIF’s chemokine-like 
functions in cells devoid of CD74, as neutrophils and fibroblast, which are also affected by 
MIF. This thesis introduces the two chemokine receptors CXCR2 and CXCR4 as 
functional receptors for MIF. MIF triggered Gαi and integrin-dependent arrest of 
monocytes and T cells specifically through CXCR2 and, to a lesser extent, CXCR4, 
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inducing rapid integrin activation and calcium influx. MIF directly bound to CXCR2 as 
revealed by FACS analysis and coimmunoprecipitation. Monocyte arrest mediated by MIF 
in inflamed or atherosclerotic arteries involved CXCR2 and CD74, which occur in a 
receptor complex. In vivo, MIF deficiency impaired monocyte adhesion to the 
aortic/arterial wall in atherosclerosis-prone mice, and MIF-induced leukocyte adhesion as 
well as peritoneal recruitment required CXCR2, as evidenced by intravital microscopy and 
MIF/CXCR2 chimeric mice. Blocking MIF but not bona fide ligands of CXCR2 or 
CXCR4 in mice with advanced atherosclerosis reduced plaque area, monocyte and T-cell 
content. These data open the possibility of achieving therapeutic regression and 
stabilization of advanced atherosclerotic lesions by targeting MIF. 
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VI Zusammenfassung 
Die vorliegende Arbeit beschäftigt sich mit der Expressionskontrolle und Effekten von 
zwei Proteinen, die eine große Auswirkung auf den Krankheitsverlauf der Atherosklerose 
haben. 
Im ersten Forschungsansatz wurde YB-1 als der Transkriptionsregulator des CC 
Chemokins RANTES identifiziert. Während einer Entzündungsreaktion wird die 
Expression von RANTES in mononukleären Zellen hochreguliert, oder RANTES wird von 
aktivierten Plättchen auf dem Endothel deponiert, wo es an der Entstehung von 
Atherosklerose und neointimaler Hyperplasie beteiligt ist. In der vorliegenden Studie 
wurde der Einfluss von YB-1 auf die RANTES-Expression, sowie seine Mitwirkung an der 
Neointimabildung nach Drahtverletzung der Carotis ermittelt. Die Bindung von  YB-1 an 
Position -214/-173 des RANTES-Promotors wurde durch DNA-Bindungsstudien bestätigt. 
Die gesteigerte Expression von YB-1 und RANTES-mRNA in neointimalen versus 
medialen glatten Muskelzellen deutete auf eine regulatorische Funktion von YB-1 für die 
RANTES-Expression hin, und tatsächlich führte die Überexpression von YB-1 in  
glatten Muskelzellen (aber nicht in Makrophagen) zu einer verstärkten RANTES-
Promotoraktivität, sowie zu einer gesteigerten Produktion von RANTES-mRNA und  
-Protein. Außerdem bewirkte die YB-1 Überexpression in glatten Muskelzellen einen 
verstärkten Monozytenarrest in Scherfluss, der durch den RANTES-Rezeptorantagonisten 
Met-RANTES signifikant inhibiert wurde. Darüber hinaus führte der lentivirale Transfer 
von YB-1 shRNA in die Karotidenlumina von hyperlipidämischen Apoe-/--Mäusen nach 
Drahtverletzung zu einer signifikant reduzierten Plaquefläche, sowie reduziertem 
Makrophagengehalt. YB-1 wurde in neointimalen SMC aber nicht in Makrophagen 
exprimiert und kolokalisierte mit neointimalem RANTES, dessen Expression durch YB-1-
Silencing herunterreguliert wurde. Eine weitere Reduktion der Neointimafläche durch  
YB-1-Silencing wurde weder in Met-RANTES-behandelten noch in RANTES-Rezeptor-
defizienten (Ccr5-/-) Apoe-/--Mäusen beobachtet. Dieser Umstand ließ darauf schließen, 
dass der YB-1-Effekt auf die Neointimabildung RANTES-abhängig war. Folglich könnte 
die lokale Blockade von YB-1 eine neue Strategie zur Restenose-Prävention nach 
Angioplastie darstellen. 
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Im zweiten Teil dieser Arbeit sollte den Funktionsmechanismen des CLF Chemokins 
MIF auf den Grund gegangen werden. MIF spielt eine wichtige Rolle bei 
Entzündungserkrankungen wie der Atherogenese und lockt Immunzellen zu 
Entzündungsherden. Der einzige bekannte Zelloberflächenrezeptor für MIF ist CD74, 
welcher eine anhaltende Aktivierung von ERK/MAPK vermitteln kann. Es wurde bisher 
jedoch kein Rezeptor gefunden, der die Chemokinfunktionen von MIF in Zellen ohne 
CD74, wie Fibroblasten und Neutrophile, erkären würde. Diese Studie identifiziert die 
zwei Chemokinrezeptoren CXCR2 und CXCR4 als funktionelle Rezeptoren für MIF.  
MIF vermittelte Gαi- und Integrin-abhängige Adhäsion von Monozyten und T-Zellen 
spezifisch durch CXCR2 und, zu einem kleineren Teil, durch CXCR4. Dabei induzierte 
MIF eine schnelle Integrinaktivierung und Calciummobilisierung. FACS Analyse und Co-
Immunpräzipitation bestätigten die direkte Bindung von MIF an CXCR2. MIF-vermittelter 
Monozytenarrest in entzündlichen oder atherosklerotischen Arterien war abhängig von 
CXCR2 und CD74, welche einen Rezeptorkomplex bilden. MIF-Defizienz verhinderte 
Monozytenarrest an der Aorta-/Arterienwand in Atherosklerose-anfälligen Mäusen in vivo, 
und, wie intravitale Mikroskopie und MIF/CXCR2-Chimäre bestätigten, war CXCR2 
verantwortlich für MIF-induzierte Leukozytenadhäsion, sowie für die 
Neutrophileninfiltration im Peritonitismodell. Die Blockade von MIF, aber nicht von den 
bekannten CXCR2/CXCR4-Liganden in Mäusen mit fortgeschrittener Atherosklerose 
reduzierte die Plaquefläche und deren Monozyten-und T-Zellgehalt.  
Die Aufklärung der Wirkungsmechanismen von MIF in dieser Studie eröffnet neue 
Möglichkeiten für Therapien zur Regression und Stabilisierung von atherosklerotischen 
Läsionen.  
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